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ABSTRACT 
 
A variety of genetically encoded tools have been developed for deciphering the neural 
circuitry of the brain. Such tools allow physical manipulation of neuronal excitability in a 
reversible, cell-specific manner, enabling researchers to establish how electrical activity 
and connectivity facilitate the information processing that mediates perception and drives 
behavior. An expanding toolkit of engineered neuroreceptors, particularly those actuated 
by orthogonal pharmacological ligands, provide noninvasive manipulation of regional or 
disperse neuronal populations with adequate spatiotemporal precision and great potential 
for multiplexing. We previously engineered an invertebrate glutamate-gated chloride 
channel (GluCl αβ) that enabled pharmacologically induced silencing of electrical 
activity in targeted CNS neurons in vivo by the anthelmintic drug compound ivermectin 
(IVM; Lerchner et al., 2007). With this receptor, GluCl opt α-CFP + opt β-YFP Y182F, 
the concentration of IVM necessary to elicit a consistent silencing phenotype was higher 
than expected, raising concern about its potential side effects. Considerable variability in 
the extent of spike suppression was also apparent and was attributed to variable co-
expression levels of α and β subunits. Thus, a rational protein engineering strategy was 
employed to optimize the GluCl/IVM tool. To increase agonist sensitivity, a gain-of-
function gating mutation involving the highly conserved leucine 9’ residue of the α pore-
lining M2 transmembrane domain was introduced. Various mutations at this position 
facilitate channel opening in the absence and presence of ligand. Analysis of side chain 
properties revealed that helix-destabilizing energy correlated with increases in agonist 
sensitivity. One mutation, L9’F, enhances β subunit incorporation to substantially 
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increase IVM sensitivity without permitting unliganded channel opening. Removal of an 
arginine-based ER retention motif (RSR_AAA) from the intracellular loop of β promoted 
plasma membrane expression of heteromeric GluCl αβ by preventing ER-associated 
degradation of the β subunit. An additional monomeric XFP mutation complements these 
effects. The newly engineered GluCl opt α-mXFP L9’F + opt β-mXFP Y182F 
RSR_AAA receptor significantly increases conductance and reduces variability in 
evoked spike generation in vitro using a lower concentration of IVM. This receptor, 
dubbed ‘GluClv2.0’, is an improved tool for IVM-induced silencing. 
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Chapter 1 
 
Introduction to Neuroscience and Neuronal Manipulation Tools 
 
The brain is the most complex and highly adaptable organ in the human body.  Every 
thought, sensation, perception, movement, motivation, emotion, mood, and memory we 
experience is produced as a continuous stream of information. This information exists as 
an encoded array of complex and simultaneous physical, chemical, and biological events 
all accomplished in the brain by individual nerve cells and the connections between them. 
 
Neurons are the Excitatory Cells of the Brain 
The human brain is composed of approximately 86 billion neurons (nerve cells) and 85 
billion nonneuronal (glial) cells organized into distinct anatomical regions1. Neurons are 
the functional unit of the brain. They are electrically excitable and their activity affects 
the electrical state of adjacent neurons. In contrast, glial cells are not directly involved in 
electrical signaling. Rather, they are deemed support cells, providing structure, 
regulation, and protection to the neurons. Glial cells also insulate the nerve cell axons and 
synaptic connections necessary for the conduction of electrical signals.  
At rest, all cells including neurons maintain a separation of positive and negative 
ions on either side of the plasma membrane. A resting nerve cell has an excess of positive 
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charge on the outside of the membrane and an excess of negative charge on the inside. 
This separation of charge creates an electrical potential difference, or voltage, across the 
membrane called the resting membrane potential. A typical quiescent neuron has a 
resting membrane potential of -65 mV. As excitable cells, neurons differ from other cells 
in their ability to rapidly and dramatically change their membrane potential.  
Rapid changes in membrane potential are mediated by ion channels. Ion channels 
are integral membrane proteins found in all cells of the body, however, those present in 
nerve cells are optimally tuned for rapid information processing. Ion channels of nerve 
cells open in response to specific electrical, mechanical, or chemical stimuli to conduct 
charge-specific ionic current at rates up to 108 ions/channel/second. Some channels are 
selective for a particular ion over others with the same charge. The most abundant, 
permeable ions in biological systems include the positively charged cations potassium 
(K+), sodium (Na+), and calcium (Ca2+), and the negatively charged anion chloride (Cl−). 
These ions are not distributed equally across the membrane; the concentration of K+ ions 
is higher inside the cell, while the concentrations of Na+, Cl−, and Ca2+ are higher outside 
the cell. This unequal distribution generates a concentration gradient. Thus, the direction 
of passive ion flow is subject to both chemical and electrical driving forces due to 
concentration and ionic charge differentials. Passive diffusion of ions down their 
electrochemical gradient will proceed until reaching the point at which the electrical 
driving force in one direction exactly opposes the chemical driving force in the opposite 
direction and there is no longer a net flow. The membrane voltage at which this occurs is 
called the equilibrium potential (or Nernst potential) for that particular ion. The 
equilibrium potential of an ion is dependent on the valence charge of that ion, z, and the 
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concentrations of that ion inside, [X]i, and outside, [X]o, of the cell, and can be calculated 
using the Nernst Equation, defined as 
 
 
where R is the universal gas constant (8.314 J K-1 mol-1), T is the temperature (in Kelvin), 
and F is the Faraday constant (9.65×10-4 C mol-1). 
At rest, a nerve cell membrane is mostly permeable to K+ ions, therefore the 
membrane voltage (resting membrane potential) is close to the potassium equilibrium 
potential, EK. A net flow of cations or anions into or out of the cell disturbs the charge 
separation across the membrane, altering the voltage. A reduction of charge separation, or 
depolarization, leads to a less negative membrane potential (e.g., from -65 mV to -55 
mV). An increase in charge separation, or hyperpolarization, results in a more negative 
membrane potential (e.g., from -65mV to -75mV).  
 
Neuronal Communication 
When depolarization approaches a critical membrane potential, called the threshold 
voltage, it triggers the opening of voltage-gated Na+ channels present in the cell 
membrane. This allows Na+ ions to flow into the cell (i.e., down their electrochemical 
gradient), causing further depolarization, which facilitates the opening of even more 
voltage-gated Na+ channels, rapidly driving the membrane potential toward ENa. In this 
!
! 
EX =
RT
zF ln
[X]o
[X]i
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depolarized state, the Na+ channels begin to inactivate, while voltage-gated K+ channels, 
which opened more slowly in response to the initial depolarization, remain open. Slow, 
outward K+ current repolarizes the membrane back its resting membrane potential. The 
entire depolarization-repolarization process occurs within a millisecond. This rapid, 
transient, all-or-nothing voltage impulse is called an action potential.  
The morphology of a typical neuron consists of (1) the cell body (soma), which 
contains the nucleus including the genes of the cell, (2) dendrites, processes which branch 
out to receive incoming signals from other neurons, (3) the axon, a single tubular 
extension which transmits the electrical signal over some distance, and (4) presynaptic 
terminals, fine branches extending from the axon that communicate the electrical signal 
at a site called the synapse to the dendrites or soma of receiving (postsynaptic) neurons 
(Figure 1-1A). The presynaptic terminal and postsynaptic cell are physically separated by 
a space known as the synaptic cleft (Figure 1-1B). At a synapse, the electrical signal is 
converted to a chemical signal, in which chemical neurotransmitter molecules are 
released from the presynaptic cell and diffuse across the synaptic cleft to activate 
receptors present on the postsynaptic membrane, where the signal is then converted back 
to an electrical potential. The sign of the signal, inhibitory or excitatory, depends on the 
type of receptors in the postsynaptic cell, not the identity of the neurotransmitter. All 
synaptic input of the receiving neuron is integrated at the axon hillock, the initial segment 
of the axon. This region of the cell membrane contains the highest density of voltage-
gated Na+ channels in the cell, and thus has the lowest threshold for spike initiation. If the 
summation of input signals reaches the threshold voltage, an action potential will be 
generated (Figure 1-1C). 
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Figure 1-1.  Neuronal communication.  A. Typical neuron morphology consists of the cell body, 
dendrites, the axon, and presynaptic terminals. The presynaptic neuron communicates the neural signal to 
the postsynaptic neuron at synapses.  B. Chemical neurotransmitter molecules packaged in synaptic vesicles 
are released from the presynaptic cell and diffuse across the synaptic cleft to activate ion channel receptors 
on the postsynaptic membrane.  C. Synaptic input of the receiving neuron is integrated at the axon hillock. 
If the summation of input signals reaches the threshold voltage, an action potential will be generated. 
 
Neural Circuits Convey Information 
An action potential initiated at the axon hillock is actively propagated along the axon, 
regenerating with constant amplitude at regular intervals, until it reaches the presynaptic 
terminals where the signal is transmitted to other cells. Input signals below threshold 
voltage will not initiate an action potential, whereas all signals above the threshold will 
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produce the same all-or-nothing action potentials in succession in a “spike firing” pattern. 
All spikes fired are the same size and shape, but they differ in frequency (i.e., the number 
of action potentials and the time intervals between them). Thus, information in the brain 
is conveyed through neuronal firing patterns and the specific pathways in which they 
travel. 
Nerve cells in the brain are highly organized into signaling pathways and have the 
same gross anatomical arrangement in every individual. Neurons are clustered into 
discrete groups that are functionally specialized for processing specific types of 
information. These regions are projected and interconnected to form extensive neural 
networks, generating sensory and motor functions, and facilitating learning, memory, and 
language abilities. The neural pathways for certain higher functions have been precisely 
mapped in the brain, though exactly how they produce complex cognition and behavior is 
still poorly understood. The majority of neurological and psychiatric disorders are 
believed to result from disruption of neural circuits caused by cellular abnormalities 
and/or molecular imbalance. Therefore, a detailed understanding of neural circuitry will 
aid in proper diagnoses and treatment strategies for such conditions.  
 
The Study of Neuroscience: A Brief Chronology 
The original notion that individual brain regions have distinct functions associated with 
different behaviors has been around since 1796 with the creation of phrenology by the 
German physician, Franz Joseph Gall. Phrenologists believed that the brain was the organ 
of the mind and that one’s personality could be determined by the variation of bumps on 
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their skull. Now considered a pseudoscience, phrenological thinking was an important 
historical advancement toward the discipline of modern neuroscience. In 1861, the 
French neurologist Pierre Paul Broca extended the idea of phrenology, arguing that 
localization of brain function should be based on examining behavior that results from 
clinical lesion of internal brain regions rather than external inspection of bumps on the 
head. A short fifteen years later, German neurologist Karl Wernicke proposed that only 
the most basic mental functions such as perception and movement were localized to 
single areas of the brain, but more complex cognitive functions resulted from 
interconnections between several anatomical sites, advancing the idea of ‘distributed 
processing’ (i.e., various components of a single behavior are processed in different 
regions of the brain). At the beginning of the twentieth century, German anatomist 
Korbinian Brodmann used a staining technique to divide the human cerebral cortex into 
52 discrete functional areas based on distinctive structural variation and characteristic 
organization of the cells. The cytoarchitectonic scheme of Brodmann areas is still widely 
used and continually updated today.   
In the days of Broca and Wernicke, everything known about brain function had 
come from studying the behavior of brain-damaged patients and determining the site of 
damage in a postmortem analysis.? If a patient had a deficit in some behavior, then 
execution of that behavior must depend on the lesioned area. In the 1920s, American 
psychologist Karl Lashley performed intentional lesion studies on laboratory animals by 
assessing the ability of a rat to complete a maze task after lesioning separate regions of 
brain cortex. A variety of animal lesion models and behavioral assays have since been 
created to associate specific brain regions with brain function. When establishing such 
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correlations, lesion models can be useful for demonstrating the necessity of an anatomical 
region, but they cannot resolve its particular role within a neural pathway. Disruption of 
adjacent brain regions during surgery or adaptive rewiring postsurgery may also 
complicate functional interpretations. Hence, lesion studies often produce confounding 
results and are not sufficient for investigating neural circuitry. 
 
Need to Manipulate Neuronal Activity 
The basic principles of brain organization, and to some extent information processing, 
have been pieced together using functional data from both brain slices (in vitro) and 
brains of awake, behaving animals (in vivo). Functional data can be obtained by various 
imaging and electrophysiology techniques, while additional pharmacological application 
and electrical stimulation can be used to directly probe neuronal function and 
connectivity. However, these methods are also limited in their ability to elucidate neural 
circuitry. Pharmacology often lacks specificity for particular cell types. Microstimulation 
excites both excitatory and inhibitory neurons and the precise region or number of 
stimulated cells is in many cases unknown.  
Absolute resolution of intact neural circuits requires the direct manipulation of 
defined neuronal populations2,3. Such manipulation entails the ability to selectively and 
reversibly turn neuronal activity on and off in a tunable way on a relevant timescale. This 
can be approached in two different ways: controlling neurotransmitter availability to 
manipulate signal transmission, or controlling neuronal membrane potential to 
manipulate signal transduction. Both strategies have been used to induce or inhibit 
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neuronal activity. Manipulation is achieved via chemical, physical or genetic influences 
on transcription or protein activation. 
Neurotransmitter availability can be restricted by preventing release into the 
synaptic cleft. For example, cleavage of vesicle-associated membrane protein 2 (VAMP2, 
also known as synaptobrevin) by inducible transcription of tetanus neurotoxin light chain 
(TeNT) can be used to inhibit synaptic vesicle fusion and subsequent neurotransmitter 
release4,5. An alternative approach called ‘Molecules for Inactivation of Synaptic 
Transmission’ (MISTs), utilizes a small molecule dimerizer to induce cross-linking of 
genetically modified forms of vesicular proteins including VAMP2 and synaptophysin to 
interfere with the protein-protein interactions necessary for vesicle fusion6. Induced 
neurotransmitter availability can be achieved with the use of caged neurotransmitters. 
With this technique, neurotransmitters are rendered biologically inactive, or caged, by 
chemical modifications with a photocleavable protecting group. A flash of light liberates 
the active form, imitating neurotransmitter release and permitting photostimulation of 
synaptic activity. Glutamate uncaging has been used extensively to study circuitry in 
vitro7, however, most mammalian neurons express glutamate receptors so the technique 
lacks cellular specificity. The usefulness of TeNT and MISTs methods for in vivo studies 
is also limited due to a slow onset (14 days) of transcriptional induction and issues with 
delivery of chemical dimerizers. Furthermore, these methods alter the activity of 
neurotransmitter molecules rather than the neuron itself, so the postsynaptic targets must 
already be known in order to confirm the manipulated effect by electrophysiology. 
Manipulation of neuronal membrane potential to control signal transduction is 
possible through modification of membrane ion channels or receptors. Rapid current flow 
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of selective ions into or out of the cell provides the dramatic changes in membrane 
potential necessary for versatile neuronal signaling. Direct alteration of the membrane 
potential can enhance the cell’s ability to generate an action potential through 
depolarization, or inhibit the cell’s ability to generate an action potential by 
hyperpolarization or shunting (clamp the Vm ≈ EK). Thus, neuronal activity can be 
induced by cation influx or silenced by K+ efflux or Cl− influx. Neurons have 
successfully been silenced by overexpression of various K+ channels8-10. Since many of 
these channels are constitutively active, induction and reversal can only be accomplished 
through transcriptional control. Overexpression of K+ channels can also yield undesirable 
effects such as disruption of native potassium channel expression or cell death11,12. 
Another effective silencing strategy uses membrane-tethered toxins to inhibit endogenous 
sodium channel or nicotinic receptor function13. Since toxins are peptides tethered to the 
membrane by a GPI anchor, they also require regulated gene expression for temporal 
control. Tethering of the ligand to the receptor with a photoisomerizable moiety 
addressed the need for controlled initiation and termination of modulating effects. 
Photoswitchable tethered ligands allow exogenously engineered channels or native 
channels to become ‘light-gated’, as light-induced isomerization presents or removes the 
ligand from its binding site14,15.  
Other strategies have involved chemically induced inhibition of neuronal activity. 
One study administered the allosteric modulator zolpidem to activate selectively 
expressed GABAA chloride channels using a transgenic mouse model in which 
endogenous GABAA channels were engineered to abolish sensitivity to zolpidem16. A 
related technique used a serotonin receptor 1A (5-HT1A) knockout mouse and targeted 
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restoration of 5-HT1A receptor expression with administration of selective serotonergic 
agonists17. Though successful, these methods unfortunately require animals with 
specialized genetic backgrounds and implement native receptors that can still be activated 
by endogenous neurotransmitters. 
 
Expression of Foreign Receptor Tools 
Many of these methods lack cell specificity, have slow temporal control, limited 
reversibility, constitutive activity, or interfere with native protein expression. Such issues 
have clarified the need for more refined control over neuronal activity.  
Detailed circuit analysis requires the ability to manipulate and monitor a specific 
cell type. Cell types may be defined by anatomical characteristics including cell body 
location, dendritic morphology, axonal projection as well as electrophysiological 
characteristics and gene expression patterns. Molecular and genetic technology has been 
used to target gene expression of foreign receptor proteins to specific neuron types that, 
when activated, can inhibit or enhance neuronal activity within complicated neuronal 
circuits.  
Genetically targeted manipulation must be precisely controlled in space and in 
time. The expression of an exogenous protein by itself should be innocuous, but when 
activated should enhance or silence neuronal firing in a selectively inducible and 
reversible manner. Many successful applications of targeted neuronal manipulation have 
involved the use of light to activate exogenous ion channels and receptor proteins. These 
include opsin proteins which are naturally light-sensitive ion channels and pumps 
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activated by photoisomerization of the chromophore retinal, a native compound of 
vertebrate nervous systems, to directly photoregulate membrane potential. Light 
activation of channelrhodopsin, an ion channel from the unicellular green algae 
Chlamydomonas reinhardtii, produces cationic currents to enable action potential firing 
that is time-locked to pulsed light18,19. Conversely, halorhodopsin, a chloride pump from 
the microorganism Natronomonas pharaonis, hyperpolarizes neurons to inhibit the 
production of action potentials20. Such optical control over neuronal activity allows 
millisecond timescale modulation. However, optical approaches require specialized 
equipment and are invasive, as light sources must be applied directly to the brain region 
of interest. Poor light penetration and heat generation also limit its applications to 
anatomically defined regions and short-termed modulations.  
Alternative approaches use small molecule agonists for activation of exogenous 
receptors and ion channels, extending manipulation capabilities to deep and disperse 
neuronal populations with virtually limitless opportunities for simultaneous applications. 
These pharmacologically induced methods come with their own advantages, limitations, 
and requirements for specificity and are described in the next chapter. One such 
pharmacological tool, GluCl/IVM, is the subject of experimentation in this thesis. 
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Abstract 
Studying the functional architecture of the brain requires technologies to precisely 
measure and perturb the activity of specific neural cells and circuits in live animals. 
Substantial progress has been made in recent years to develop and apply such tools. In 
particular, technologies that provide precise control of activity in genetically defined 
populations of neurons have enabled the study of causal relationships between and among 
neural circuit elements and behavioral outputs. Here, we review an important subset of 
such technologies, in which neurons are genetically engineered to respond to specific 
chemical ligands that have no other pharmacological effect in the central nervous system. 
A rapidly expanding set of these “orthogonal pharmacogenetic” tools provides a unique 
combination of genetic specificity, functional diversity, spatiotemporal precision and 
potential for multiplexing. We review the main orthogonal pharmacogenetic technologies 
that utilize engineered neuroreceptors to control neuronal excitability. We describe the 
key performance characteristics informing the use of these technologies in the brain, and 
potential directions for improvement and expansion of the orthogonal pharmacogenetics 
toolkit to enable more sophisticated systems neuroscience. 
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Introduction 
The brain is a complex system comprising billions of interconnected, specialized cells 
whose collective function gives rise to mental states and observable behavior, while 
malfunction leads to neurological and psychiatric disease. Studying this system requires 
technologies to precisely sense and control the activity of specific neural cells and 
circuits in model organisms. An important focus of technical development in recent years 
has been technologies that provide precise control of activity in genetically defined 
populations of neurons. Such technologies have enabled the study of causal relationships 
between the functioning of neural circuits and behavior, yielding novel insights into 
processes such as aggression1, anxiety2 and appetite3. Here, we review an important 
subset of such technologies, in which exogenous genes introduced into neurons enable 
them to respond to specific chemical ligands that have no other pharmacological effect in 
the central nervous system (CNS). An expanding repertoire of such tools provides a 
powerful combination of genetic specificity, functional diversity, spatiotemporal 
precision and potential for multiplexing that will be critical in obtaining a systems-level 
understanding of brain function.  
In the past, neuroscientists have modulated neural activity using pharmacology or 
electrical stimulation, obtaining either molecular or spatial specificity (Table 2-1). Each 
method is incomplete, since both location and molecular identity are needed to define the 
functional circuit roles of neurons. Recently, novel technologies have been developed 
that are capable of controlling neural activity with both spatial and molecular precision. 
These technologies take advantage of advances in understanding of cell type-specific 
gene expression in neurons4 and methods of targeting transgenes to cells based on their  
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Table 2-1.  Capabilities of neural control technologies 
 
genetic properties, location and circuit connectivity5. Control is achieved by expressing 
exogenous actuator proteins that make specific neurons responsive to “orthogonal” 
stimuli that normally have no effect on nervous system function. 
One successful instantiation of this concept, “optogenetics”, uses actuator proteins 
that are sensitive to visible light, including ion channels, transporters, G-protein coupled 
receptors (GPCRs) and protein-protein binding domains. Expressing these proteins in 
neurons makes it possible to control various aspects of their activity with light6-8. In 
addition to the molecular, spatial and circuit specificity achievable through genetic 
targeting, optical stimulation provides a high degree of temporal precision, in some cases 
on millisecond timescales enabling control of neuronal spike timing and frequency9 
(Table 2-1). Multiplexing is possible with up to 3–4 channels using actuator proteins that 
respond to different wavelengths. A drawback of optogenetic brain stimulation in 
mammals is the need for implanted optical fibers to deliver light. In addition to being 
Conventional 
Pharmacology 
Electrical 
Stimulation Optogenetics 
Orthogonal 
Pharmacogenetics 
Cell type specificity Medium None High High 
Temporal precision Medium High High Medium 
Spatial precision None High High Medium 
Multiplexing Low Low Medium High 
Signaling variety Low Low Medium High 
Spatial Coverage High Low Low High 
Requires gene 
delivery No No Yes Yes 
Requires device  No Yes Yes No 
	   19	  
burdensome experimentally, the resulting localized illumination makes it difficult to 
control diffuse signaling networks. 
Another approach to orthogonal control of genetically specified neurons uses 
actuator proteins that respond to unique chemical ligands that have no other 
pharmacological activity in the CNS. This approach, to which we refer as orthogonal 
pharmacogenetics (OP), has been used for some time to control gene expression (e.g. 
using tetracycline-dependent transcriptional promoters). Recently, novel actuator proteins 
have been developed that enable chemical control of neuronal firing, second-messenger 
signaling and synaptic function. Like optogenetics, OP can use genetic targeting to 
achieve molecular, spatial and circuit specificity. In addition, ligands with different 
pharmacokinetic properties can be used to specify the timescale of neural control, ranging 
from minutes to days. This temporal resolution is not so high as with optogenetics. 
However, it is fully satisfactory in many cases where circuits play modulatory roles or the 
objective of the perturbation is long-term inhibition. Unlike optogenetics, OP does not 
require invasive implants, and both local and diffuse groups of neurons can be controlled 
depending on where the actuator gene is expressed (Table 2-1). In theory, OP also has the 
capacity for virtually unlimited multiplexing, as long as a sufficient number of unique 
ligand-receptor pairs can be developed. Importantly, such multiplexing can be both 
within a cell type (e.g., by expressing inhibitory and excitatory ion channels controlled by 
different ligands) and between multiple cell types (Figure 2-1). 
 
	   20	  
 
 
Figure 2-1.  Illustrated example of multiplexed orthogonal pharmacogenetics.  A. Two cell types (blue 
and orange) involved in a particular neural circuit (top) are genetically modified to express orthogonal 
actuators responding to several distinct ligands that can be administered orally to the model organism 
(bottom).  B. One neuron (orange) expresses four distinct OP constructs, enabling temporally specific, 
multiplexed control of excitation (ion channel controlled by ligand A), inhibition (ion channel controlled by 
ligand B), gene transcription (transcriptional transactivator controlled by ligand C) and decreased 
presynaptic transmitter release (vesicle protein multimerization controlled by ligand D). A second neuron 
(blue) has an orthogonal GPCR coupled to an endogenous potassium channel, enabling orthogonal 
inhibition under control of ligand E.  C. Using the five ligands corresponding to different orthogonal 
actuators, it is possible to test 32 binary (ligand on or off) experimental conditions in this system. 
 
OP systems have been engineered to provide chemical control over various 
aspects of neural activity, including ion channel and GPCR signaling, gene transcription 
and synaptic function. In addition, OP actuators have been developed providing control 
over gene translation and enzymatic activity that could be adapted to neurons. Below, we 
highlight the major categories of recently developed OP systems and their applications in 
neuroscience. We evaluate them with reference to a common set of performance 
characteristics applicable to functional actuators (orthogonality, compatibility, modularity 
and deliverability) their chemical effector ligands (molecular specificity and 
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deliverability), and the combination of ligand and actuator (temporal response, dose 
response), as defined in Table 2-2.  
 
 
Table 2-2.  Performance characteristics of orthogonal pharmacogenetic systems 
Actuator characteristics 
Orthogonality 
Actuator is insensitive to endogenous ligands or other signaling elements. Actuator 
inactive until triggered by ligand (or inactive in presence of ligand in a switch-off 
system). 
Compatibility Endogenous machinery needed for actuator performance is present in target cells. Actuator does not interfere with normal cell function unless it is activated by ligand. 
Modularity Actuator can be modified to produce different signaling effects upon ligand binding. 
Deliverability 
Actuator can be delivered to target cells by viral vectors and through transgenesis. 
Ideally, the essential genetic payload should be a single gene smaller than 1.5kb to 
enable single AAV construct delivery.  
Effector ligand characteristics 
Molecular 
specificity 
At the effective dose, ligand acts only on its corresponding actuator. 
Deliverability Ligand is bioavailable, preferably per orum, and penetrates CNS. 
System characteristics 
Temporal 
response 
On and off kinetics for cellular and behavioral response after administration as 
determined by ligand pharmacokinetics and receptor activation, inactivation and 
second-messenger signaling. 
Dose response Dependence of cellular and behavioral response on ligand dose.  
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Orthogonal neuroreceptors: LGICs and GPCRs  
The most active recent area of development in OP has focused on neuroreceptors. Both 
ligand-gated ion channels (LGICs) and GPCRs have been developed as orthogonal 
actuators by identifying or engineering receptors with minimal sensitivity to endogenous 
neurotransmitter agonists and strong activation by specific exogenous ligands that have 
no other significant pharmacological effect in the CNS. Targeted expression of these 
orthogonal receptors permits temporally controlled excitation or inhibition of neurons 
through the administration of their cognate ligands. 
The first orthogonal GPCR and LGIC systems for use in neuroscience were based 
on receptors from nonmammalian organisms. The Callaway group developed a system 
based on the Drosophila allatostatin receptor (AlstR) and its cognate neuropeptide ligand 
allatostatin (AL), neither of which is expressed in mammals10. AL does not cross-activate 
endogenous mammalian GPCRs, nor is AlstR activated by mammalian GPCR ligands11. 
Activation of heterologously expressed AlstR by AL leads to Gi-coupled activation of 
endogenous mammalian G protein-gated inward rectifier K+ (GIRK) channels, leading to 
a reduction in cell excitability (Figure 2-2). Virally targeted expression of AlstR in 
cortical and thalamic neurons and intracranial administration of AL produce neuronal 
silencing on a timescale of minutes in several species12. 
Around the same time, the Lester group adapted the C. elegans glutamate-gated 
chloride channel (GluCl) for silencing of mammalian neurons by administration of the 
anthelmintic GluCl agonist ivermectin (IVM). GluCl was rendered insensitive to its 
native ligand glutamate by a single point mutation and codon-optimized to achieve 
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greater expression in mammalian cells13,14. IVM activation of GluCl α and β subunits 
expressed in neurons elicits a Cl− conductance across the membrane that effectively 
shunts action potential generation15 (Figure 2-2). The GluCl/IVM system later became 
the first to be used for neuronal silencing with a systemically administered ligand in 
awake, behaving animals16. 
More recently, versatile orthogonal neuroreceptor systems have been established 
by modifying mammalian GPCRs and LGICs. A collection of modified GPCRs called 
DREADDs, “designer receptors exclusively activated by designer drugs”, were 
developed using a combination of directed evolution and rational protein engineering17. 
Building on previous efforts to engineer the ligand selectivity of GPCRs18, the first 
DREADDs were generated from the human M3 muscarinic receptors (hM3). Survival 
screens based on the yeast pheromone response19 were used to evolve this receptor for 
activation by the small molecule clozapine-N-oxide (CNO) and lack of activation by the 
native ligand acetylcholine. CNO is a normally inactive metabolite of the atypical 
antipsychotic clozapine. CNO activation of the mutant hM3D triggers Gq-coupled 
signaling leading to membrane depolarization through phospholipase Cβ (PLCβ)/PIP2 
mediated inhibition of KCNQ channels20 (Figure 2-2). Following a similar design 
scheme, a second CNO-activated DREADD, hM4D, was generated that couples to Gi, 
leading to activation of GIRK channels and neuronal silencing similar to that elicited by 
AlstR/AL (Figure 2-2).  
Recently, a systematic engineering approach was also taken to the development of 
a modular system of orthogonally controlled Cys-loop ion channels with distinct ligand 
sensitivity and ion conductance properties3. The modularity of this system is based on 
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fusing the α7 nicotinic acetylcholine receptor (nAChR) ligand-binding domain onto the 
ion pore domain of either a cation-selective serotonin 5-HT3 receptor (α7-5HT3) or 
anion-selective glycine receptor (α7-GlyR) to produce functional channels with the same 
pharmacological profile but different ion permeability21,22. Novel ligand recognition 
properties were engineered through a “bump-hole” approach, which uses structural 
models to generate libraries of predicted ligand-receptor pairs that are then synthesized 
and screened for selective functional activity. Structural analogs of the α7-specific 
synthetic agonist PNU-282987 were tested for selective activation of mutant, but not 
wild-type, channels. At the same time, mutant channels were screened for lack of 
activation by acetylcholine and nicotine.  The resulting mutant ligand binding domains 
are dubbed ‘pharmacologically selective actuator modules’ (PSAMs). Each PSAM is 
exclusively activated by a cognate synthetic agonist, called a “pharmacologically 
selective effector molecule” (PSEM). Three specific PSAM/PSEM tools have been 
designed, each with different ion conductance properties for controlling neuronal 
excitability3. These include the cation-selective activator, PSAMQ79G,Q139G-
5HT3HC/PSEM22S, the anion-selective silencer, PSAML141F,Y115F-GlyR/PSEM89S, and a 
third Ca2+-selective channel, PSAMQ79G,L141S-nAChR V13’T/PSEM9S. 
Another orthogonal LGIC system is based on the transient receptor potential ion 
channel TRPV1, an endogenous mammalian receptor predominantly expressed in the 
peripheral nervous system. TRPV1 is a nonselective cation channel activated by noxious 
heat, pH and exogenous ligands including the hot chili pepper compound capsaicin23. 
Targeted neuronal expression of TRPV1 in the mouse brain leads to capsaicin-activated 
currents and action potentials24. To use TRPV1 for orthogonal control of specific 
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neurons, the host organism can be modified to knock out endogenous TRPV1 expression. 
On this TRPV1-/- background one can reintroduce TRPV1 into target cells as an 
exogenous OP actuator25. 
 
 
 
Figure 2-2.  Mechanisms of orthogonal neuroreceptors.  GPCRs form the basis for both excitatory and 
inhibitory OP systems (A, D) based on interactions with different endogenous G proteins. GPCR signaling 
cascades leading to excitation and inhibition are described in the text. Cys-loop LGICs (B, E) are also used 
to effect inhibition and excitation based on pore domain ion selectivity. TRPV1 (C) excites cells through a 
nonselective cation conductance. 
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Performance Characteristics 
The set of available OP neuroreceptor tools is summarized in Table 2-3. Their specific 
performance characteristics inform their ability to fulfill the unique objectives of a 
neuroscience study. As defined in Table 2-2, key performance characteristics depend on 
the properties of actuators, effectors, or both. 
 
Actuator orthogonality, compatibility, modularity and deliverability 
GPCR and LGIC architectures of orthogonal receptors confer distinct functional 
properties.  Neural control using GPCR-based systems depends on second messenger 
signaling cascades. Although these secondary effectors are generally present in neurons, 
their precise quantity and subcellular localization could impose limits on actuator 
function. Conversely, expression of heterologous receptors could sequester second 
messenger molecules, disrupting endogenous receptor activity26. G-protein-mediated 
cascades may also have undesirable effects beyond altering neuronal firing (e.g., 
affecting gene expression), especially with sustained activation27,28. In contrast to 
GPCRs, LGIC actuators are self-contained membrane proteins with ligand-dependent 
ionic conduction directly affecting membrane excitability. They require no intermediary 
molecules. However, close attention must be paid to their ionic selectivity. The high Ca2+ 
permeability of TRPV1, for example, is likely to trigger Ca2+-mediated cell signaling 
events in addition to exciting cells. 
Both LGICs and GPCRs are functionally modular. The PSAM/PSEM system 
described above illustrates the relative ease of generating new chimeric channels based 
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on the modularity of Cys-loop receptors. Ligand-binding domains developed and tested 
while connected to one transmembrane domain were transplanted onto other 
transmembrane domains, resulting in constructs with completely different ionic 
conductance. Structure-function studies support further potential for altering ion 
selectivity, single-channel conductance, and open channel duration (reviewed in29-31). 
When modifying Cys-loop receptors, one must ensure that mutant channels have minimal 
leak current in the resting state. GPCRs are modular with regard to their second 
messenger coupling. Domain swapping and point mutations of intracellular loops can 
alter G-protein specificity, allowing modulation of Gi-, Gs-, and Gq-coupled signaling 
pathways32. 
Engineered receptors can be delivered into the CNS via transgenic modification 
or viral vectors. With coding sequences of approximately 1.7 kb for the M3 muscarinic 
receptor, 1.2 kb for AlstR, 1.4 kb for GluCl, 1.5 kb for PSAMs and 2.5 kb for TRPV1, 
each receptor construct can be accommodated by lentiviral vectors; in addition, GluCl, 
AlstR and PSAMs can be delivered by adeno-associated virus (AAV). Most of these tools 
require the delivery of only one genetic construct, except GluCl, which requires α and β 
subunits. The requirement for two constructs permitted GluCl to be used with 
intersectional genetic targeting33. Codon optimization and signal peptide fusions can 
improve translation and membrane trafficking of nonnative receptors14,34-36. Receptors 
can also be regionally targeted to somato-dendritic, axonal, or postsynaptic sites37-39. 
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Table 2-3.  Orthogonal neuroreceptors. Far-right columns indicate corresponding references. 
 
Ligand deliverability and specificity 
Ligands with good pharmacokinetics, including oral bioavailability and brain penetration, 
allow manipulation of deep brain structures and dispersed neuronal populations. The 
ability to conveniently deliver effector ligands is a key advantage of the DREADD/CNO, 
GluCl/IVM, and the PSAM/PSEM systems (Table 2-4). No specialized equipment is 
necessary, as the exogenous activating ligands of these tools allow convenient systemic 
administration of rapidly diffusible agonists orally or by intraperitoneal or intravenous 
injection. The bioavailability (i.e., degree to which the drug becomes available to the 
target tissue after administration) depends on its ability to cross the BBB. On the other 
hand, neuronal manipulation using AlstR/AL or TRPV1/capsaicin (in a wild-type 
background) requires localized application of their effector ligands via parenchymal or 
Class Actuator Effector 
Effect on 
neurons 
Signaling and 
Endogenous Partners 
Design & Proof-
of-concept Refs. 
Application 
Refs. 
GPCR AlstR  
drosophila 
AL Inhibition Gi-coupled; activates 
GIRK K+ channel 
10, 12, 46 56-58 
GPCR DREADD hM4Di 
human 
CNO Inhibition Gi-coupled; activates 
GIRK K+ channel  
17 59, 61-62 
GPCR DREADD hM3Dq 
human 
CNO Excitation Gq-coupled; inhibits 
KCNQ K+ channel 
17, 20 60-62 
LGIC GluCl ! & "#
C. elegans 
IVM Inhibition Cl- channel 13-16 1, 33 
LGIC PSAM-5HT3HC  
human-mouse 
PSEM22S Excitation Cation channel 
(Na+ ! K+ > Ca2+) 
3 
LGIC PSAM-GlyR  
human 
PSEM89S Inhibition Cl- channel 3 3 
LGIC PSAM-nAChR V13'T 
human-rat 
PSEM9S Not shown Ca2+ channel 3 
LGIC TRPV1 
rat 
Capsaicin Excitation Cation channel 
(Ca2+ > Na+  ! K+ )  
24-25 
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Table 2-4.  Key effector ligands used in orthogonal pharmacogenetic systems.  The * indicates 
timescales inferred from behavioral or signaling response. Far-right column indicates corresponding 
references. 
 
intracerebroventricular administration. AL is a neuropeptide that cannot cross the BBB. 
In wild-type background, systemically administered capsaicin would elicit unwanted 
effects via endogenous TRPV1 receptors. 
To achieve truly orthogonal control, effector ligands must have no significant 
activity in cells not expressing their partner actuator at doses used for actuation. IVM is 
known to activate or potentiate other Cys-loop receptors present in the CNS, but with 
much lower sensitivity40-43. PSEMs were screened for ligand binding by radioligand 
displacement against a number of other LGICs, GPCRs and transporters3, revealing weak 
to moderate binding of PSEM89S to the α4β2 neuronal nAChR receptor; off-target 
functional activation remains to be assayed. Conversely, undesired on-target effects can 
result from agonism by endogenous ligands. For example, endogenous TRPV1 ligands 
including the endocannabinoid anandamide and N-arachidonoyl-dopamine are expressed 
Ligand Origins Specificity CNS  
penetration 
Bioavailability Kinetics Refs. 
Clozapine-N-oxide 
(CNO) 
Inactive metabolite 
of clozapine 
No known activity 
at effective dose 
Yes Oral On: 5-10m 
Clearance: 2h 
20 
Allatostatin 
(AL) 
Natural 
neuropeptide 
No known activity 
in mammals 
No Injection only On: 1-3m 
Clearance: 40-60m* 
(ICV) 
12, 46, 56 
Ivermectin 
(IVM) 
Anthelmintic Specific up to 10X 
effective dose 
Yes Oral On: 4-12h* 
Clearance: 2-4d* 
16, 33 
PSEM89s Synthetic derivative 
of nAChR agonist 
PNU-282987 
Minimal binding to 
endogenous 
nAChRs 
Yes Oral On: 15m 
Clearance: 1-2h 
3 
Capsaicin Pepper ingredient, 
natural TRPV1 
agonist 
Acts on native 
TRPV1 receptors 
unless they are 
knocked out 
Yes Oral On: 2-5min 
Clearance: <15min 
25  
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in the CNS44,45 and could possibly allow capsaicin-independent enhancement of neuronal 
activity. For each system it is important to determine an effective dosage range for 
optimal control with minimal side effects. 
 
Temporal resolution and dose response 
The activation and deactivation kinetics of in vivo neuronal manipulation using OP 
systems can range from minutes to hours and depend on the pharmacokinetic properties 
of the ligand such as absorption, distribution, metabolism and excretion, as well as 
receptor properties including affinity for agonist, desensitization and internalization. The 
TRPV1/capsaicin tool allows the most rapid, transient neuronal activation, with 
excitatory responses occurring within minutes of administration and lasting 
approximately 10 minutes, attributed to rapid capsaicin metabolism25. Activation of 
DREADDs by CNO can also be observed within 5-10 minutes of drug administration, 
with induced behavior lasting from minutes to many hours. GPCRs are especially 
sensitive to desensitization and/or internalization with prolonged ligand exposure. These 
processes can either terminate a pharmacologically induced signal prematurely or 
facilitate sustained signaling or hyperexcitability46 as endocytosis of GPCRs does not 
always terminate the signal47. CNO itself is cleared after approximately 2 hours20. IVM-
induced GluCl currents activate over several hours and remain open for times on the 
order of 8 hours, presumably because neither desensitization nor ligand dissociation 
occur. Silencing effects by GluCl/IVM can last for 2–4 days; postsilencing recovery may 
actually require receptor turnover16. Long periods of enhanced or silenced activity can be 
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beneficial in some experiments, but present the risk of adaptive, compensatory, or plastic 
changes at the cellular or network levels.  PSAMs are activated by their ligands within 15 
minutes and recovery is observed after 24 hours. 
Where temporal response depends on desensitization kinetics, it may be possible 
to modify it at the actuator level. Mutations in the ligand binding domain, transmembrane 
domains and the large cytoplasmic domain of Cys-loop receptors have all been shown to 
affect desensitization48-51. For TRPV1, a point mutation that reduces Ca2+ permeability 
also abolishes desensitization52. Phosphorylation is also known to effect desensitization 
of many membrane receptors52-54. The removal of phosphorylation sites in the C-terminus 
of a heterologously expressed GPCR produced receptors that were resistant to 
internalization and less prone to desensitization, resulting in prolonged signaling55. For 
applications requiring more defined endpoints, it may be possible to design synthetic 
antagonists or selective pore blockers for controlled termination of manipulated activity. 
Thus, there would be both an “on” ligand and an “off” ligand. 
Dose-dependence of behavioral responses has been reported for Alst/AL56 and 
GluCl/IVM16 and dose-dependent increases in neuronal activity have been demonstrated 
with hM3Dq/CNO20 and TRPV1/capsaicin24,25. There is no in vivo dose-response info for 
the PSAM/PSEMs.  
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Applications of Orthogonal Neuroreceptors 
Several orthogonal neuroreceptor systems have been used in vivo to study neural circuitry 
(Table 2-3). Viral-mediated expression of AlstR has been targeted to somatostatin-
expressing neurons of the ventrolateral medulla to study pathological breathing patterns 
of adult rats56. Transgenic mouse lines expressing AlstR have been used to examine 
locomotor activity in V1 and V3 spinal cord neurons57,58.  
GluCl/IVM-induced silencing has been used in conjunction with 
channelrhodopsin-2 (ChR2) mediated activation to define an inhibitory microcircuit 
within the amygdala involved in mouse fear conditioning33. Because the GluCl channel 
requires co-expression of α and β subunits, an intersectional approach was used to 
restrict the expression of GluCl to specific GABAergic neurons within an anatomically 
defined amygdala subregion.  
Viral vectors bearing different gene promoters have been used for targeted 
expression of the hM4Di/CNO DREADD silencer in striatonigral vs striatopallidal 
neurons to study the opposing roles of direct and indirect pathways in regulating 
adaptations from repeated psychostimulant drug exposure59. Recently, the hM3Dq/CNO 
activator was expressed in an activity-dependent manner to examine how artificial 
reactivation of a stimulated network affects the encoding of contextual fear memory in 
mice60. The hM4Di/CNO silencer and hM3Dq/CNO activator tools have also been used 
in parallel experiments to study the opposing impact of activation and silencing of agouti-
related protein (AgRP) neurons of the hypothalamus on feeding patterns and energy 
expenditure61. Controlled activation and inhibition of orexinergic neurons in the 
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hypothalamus elucidated their role in controlling sleep and wakefulness62. Because CNO 
activates both excitatory and inhibitory DREADD actuators, opposite effects had to be 
studied in separate cohorts of animals. 
Simultaneous bidirectional control of neuronal activity has been demonstrated by 
OP and optogenetic actuators in the same set of cells. A bicistronic Cre-dependent AAV 
was used to co-express the PSAML141F,Y115F-GlyR silencer and the light-activated channel 
ChR2 in AgRP neurons. Voracious feeding behavior evoked from continuous 
photostimulation was strongly suppressed by intraperitoneal administration of PSEM89S3. 
Such bidirectional modulation will be most informative for deciphering neuronal 
networks and their role in behavior. 
 
	   34	  
Prospects for Further Engineering of Orthogonal Neuroreceptors 
The systems described above represent a promising start for the use of OP to control 
neural activity, demonstrating actuation of various aspects of neuronal signaling over a 
range of timescales, triggered conveniently by peripheral ligand administration. 
Substantial further work is needed to enact the vision presented in Figure 2-1. 
Multiplexed control over a significant number of cell types will require a larger set of 
orthogonal ligand-receptor pairs. Investigators should be able to choose among OP 
systems with various of temporal profiles to meet experimental requirements. More 
precise control over cellular signaling also necessitates greater “cassette” modularity of 
ligand interaction and signaling domains.  
Further development of OP neuroreceptor systems will be aided by increasing 
knowledge about receptor structure. The three-dimensional structures of a number of 
GPCRs and Cys-loop receptors have now been resolved, including the M3 muscarinic 
receptor63 and the GluCl channel64. Structures have also been solved for various 
conformational states, mutant forms and ligand complexes65. Growing availability of 
structural data along with homology modeling and docking programs will be useful in 
optimizing current tools and in rational construction of new ones. Already the 
PSAM/PSEM system has demonstrated the utility of homology-based structural 
information.  
A major goal of future OP receptor engineering efforts should be to expand the 
repertoire of ligand-receptor pairs. Most ligands used to date are either active on the 
native receptor or are close relatives of known agonists (Table 2-4). Many molecules with 
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desirable properties (lack of activity on endogenous targets, high CNS penetration, rapid 
PK) exist outside of this constrained chemical space. Antimicrobial medications and 
inactive drug metabolites, for example, are sizeable categories of compounds with 
characterized pharmacokinetics and lack of activity in mammals. An even larger 
repository of potential effector ligands may be found among inactive analogs of drug 
candidates synthesized and characterized by pharmaceutical firms during lead compound 
optimization. 
Engineering receptors that respond to effectors dissimilar from their native 
ligands could build on previous accomplishments using directed evolution17 and 
structure-guided modification3. Directed evolution, in particular, has been successful in 
altering the chemical substrate and ligand specificity of enzymes and allosteric 
switches66,67. Directed evolution requires efficient high-throughput screens, which are 
available for both GPCR signaling17 and ion channel conductance68. Furthermore, 
directed evolution libraries based on structure-guided recombination between 
homologous proteins (or domains) have been shown to enhance evolution efficiency69. 
The substantial homology of receptors and ligand-binding domains within and among 
organisms could enable the use of homologous recombination in OP receptor 
engineering. 
 
 
 
	   36	  
Conclusions 
Systems neuroscience research is now more tractable than ever thanks in part to 
molecular technologies enabling precise sensing and control of neural activity. We have 
reviewed an important class of such technologies, which provides a chemically 
addressable orthogonal dimension for neural control, and whose development is a highly 
active area of research. While a number of orthogonal pharmacogenetic tools have been 
used in neuroscience to great effect, many more (including those originally developed for 
use outside the brain) are ready for application. Future engineering efforts are expected to 
increase the variety of neuronal signaling pathways that can be manipulated. In addition, 
we believe it is particularly important to expand the repertoire of CNS-compatible ligands 
used in OP to enable multiplexed interrogation within and across cell types. Here, we 
have focused on the use of OP tools in neurons, but other relevant cell types in the brain 
such as glia and endothelial cells may also be targets for application. 
A key feature of this class of technologies is the ability of many OP tools to be 
triggered noninvasively through peripheral ligand administration. The use of these tools 
together with new technologies for high-resolution noninvasive molecular imaging will 
make it possible to create complete noninvasive neural input/output systems to study 
brain-wide neural circuits, complementing more localized research using optical 
techniques. Furthermore, as gene and cell therapy make progress towards clinical 
acceptance, it may be possible for genetically encoded OP and noninvasive imaging 
technologies to help diagnose and treat neurological disease. Thus, orthogonal 
approaches for interfacing with the brain point in an exciting direction for both basic and 
clinical neuroscience. 
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Chapter 3 
 
Mutation of a Highly Conserved Pore-Lining Leucine Residue Increases 
Agonist Sensitivity of GluCl 
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Abstract 
The glutamate-gated chloride channel (GluCl) is an invertebrate, ligand-gated anion 
channel of the Cys-loop receptor family. It is activated by the endogenous 
neurotransmitter glutamate and by the antiparasitic drug ivermectin (IVM). A crystal 
structure of the Caenorhabditis elegans GluCl α homopentamer shows the location of the 
glutamate binding site, the separate ivermectin binding site, and the highly conserved 
leucine residue at the 9’ position of the pore-lining M2 transmembrane domain.  Mutation 
of this L9’ residue in other Cys-loop receptors dramatically increases agonist sensitivity.  
Using whole-cell patch clamp, we found that six of seven mutations (L9’S, A, F, I, T, V, 
but not G) at this position in the α subunit increased the glutamate sensitivity of the 
heteromeric GluCl αβ channel by factors of 5- to 90-fold. Beta-branched amino acids 
(Ile, Thr, Val) gave the greatest reductions in EC50. Analysis of side chain properties 
revealed that helix-destabilizing energy correlated with increased glutamate sensitivity. 
Many L9’ mutations also increased background conductance, suggesting a higher 
probability of unliganded openings. Only one mutation, L9’F, resulted in increased 
glutamate sensitivity without increasing spontaneous activity. A fluorescent membrane 
potential assay confirmed that the L9’F mutation also increased IVM sensitivity. In 
addition, it was determined that GluCl α homomers indeed form functional, IVM-
sensitive channels in mammalian systems. However, GluCl α homomers bearing a L9’F 
mutation do not show increased sensitivity to IVM, implying incorporation of the β 
subunit is necessary for the gain-of-function effect. Increasing GluCl sensitivity to 
ivermectin will benefit its use as a neuronal silencing tool. 
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Introduction 
Ion channel receptors of the Cys-loop superfamily are known to mediate fast-synaptic 
transmission in vertebrate and invertebrate nervous systems. Vertebrate receptors include 
the nicotinic acetylcholine (nAChR), serotonin (5-HT3R), γ-aminobutyric acid type A and 
C (GABAA/CR), glycine (GlyR), and zinc-activated (ZAC) receptors. Invertebrate 
receptors include a variation of channels gated by these same neurotransmitters in 
addition to others gated by glutamate (GluCl), histamine (HisCl), tyramine (LGC-55), 
and pH (pHCl, SsCl). Each class of receptors is comprised of a variety of species-specific 
subunits, capable of forming receptor subtypes with different functional properties. Each 
individual Cys-loop receptor is a pentameric complex, with five subunits symmetrically 
arranged around a central ion-conducting pore. Receptor subtypes are typically 
heteromeric, however subunits of some receptor classes can form functional and 
physiologically relevant homomers. All subunits share a common topology composed of 
a large N-terminal extracellular domain, four helical transmembrane domains (M1–M4), 
and a variable intracellular loop (M3–M4 loop). The helical M2 domain of each subunit 
lines the channel pore. Activation of Cys-loop receptors by their respective 
neurotransmitter gates the entry and/or exit of specific ions through this pore, resulting in 
a change in membrane potential. 
The glutamate-gated chloride (GluCl) channel is an invertebrate Cys-loop 
receptor with a distinct pharmacological profile. GluCl chloride currents are gated by the 
traditional neurotransmitter glutamate and the semi-synthetic anthelmintic drug 
ivermectin (IVM). A 3.3-Å-resolution crystal structure of a modified homomeric GluCl 
channel reveals the binding site locations for each of these agonists (Figure 3-1A, B)1. 
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Glutamate binds at the classical neurotransmitter binding site located in the extracellular 
domain at the interface of two subunits. Ivermectin binds at a separate, unconventional 
site, inserting at the upper periphery of the transmembrane helices also at the interface of 
two adjacent subunits. Structural coordinates of the channel represent an open-pore 
conformation with the side-chains of pore-lining residues clearly defined (Figure 3-1C, 
D). One pore-lining residue, leucine 9’ (L9’), resides in the middle of the M2 
transmembrane domain. L9’ is highly conserved among subunits of the Cys-loop receptor 
family and has been proposed to serve as a hydrophobic channel gate (Figure 3-1E, F)2-4. 
Many studies using various Cys-loop receptors have shown that mutation of L9’ 
to one of several other residues can dramatically increase agonist sensitivity, apparent by 
a leftward shift in the dose-response curve, allowing channel activation with lower 
concentrations of agonist5-13. Increases in agonist sensitivity have been attributed to 
effects on channel gating resulting in longer open channel dwell times5,6,10,11,14. Other 9’ 
mutational effects have also been described including slowed apparent desensitization5-
8,11,12 and increased spontaneous activity. Spontaneous activity has been indicated by both 
a large resting conductance that is sensitive to open pore blockers9,12,14-17 as well as single 
channel events observed in the absence of agonist5,14,17. L9’ mutations may also render 
some partial agonists as full agonists18 or even convert an antagonist into an agonist19. In 
contrast, some L9’ mutant studies have shown no increase in agonist sensitivity8,16,20,21, 
no increase in spontaneous activity16,20, or no blockade of a large resting conductance 
with specific channel blockers21 for a selection of L9’ mutations. These inconsistencies 
could be due, in part, to the assortment of amino acids substituted into the L9’ position. 
For example, it has been consistently reported that polarity of the amino acid mutation 
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influences the gain in agonist sensitivity for several cationic receptors, with more polar 
amino acids showing a greater reduction in EC50 for the muscle type nAChRs10,11, 
neuronal α7 nAChRs7, and 5-HT3Rs8. Aside from this, no other correlations between the 
functional behavior displayed by L9’ mutant receptors, (e.g., cationic versus anionic, 
heteromeric versus homomeric) and the identity of the amino acid substitution have been 
determined. 
The current study investigates the effect of seven different L9’ mutations in the 
Caenorhabditis elegans GluCl receptor. Mutational effects are examined by assaying 
electrophysiological responses in the presence and absence of agonist as well as changes 
in membrane potential using a voltage-sensitive fluorescent dye. The L9’ gain-of-
function effect has been examined exclusively using traditional neurotransmitter agonists. 
It is unclear whether an L9’ mutation would enable a similar increase in sensitivity for an 
agonist activating the channel at a different binding site location on the receptor, such as 
IVM. An L9’ mutation that allows GluCl to be activated by a lower concentration of IVM 
would be beneficial toward the application of GluCl/IVM as an electrical silencing tool in 
mammalian neuronal circuitry studies22,23. 
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Figure 3-1.  The GluCl channel.  A. Crystal structure (side view) of a modified GluCl α homomeric 
channel with glutamate and IVM molecules bound (3RIF.pdb). Agonists bind at subunit interfaces; 
glutamate binds in the extracellular domain, IVM binds at the top half of the transmembrane domain.  B. 
GluCl is differentially activated by glutamate and IVM. Electrophysiological traces were obtained from 
heteromeric GluCl αβ channels expressed in Xenopus oocytes (figure adapted from Li et al., 200224).  C. 
Top view of the GluCl channel showing symmetrical arrangement of subunits forming the pore.  D, E, & F. 
Residues of the helical pore-lining M2 domain. Leucine 9’ is a highly conserved pore-lining residue. 
(Figure D. adapted from Hibbs & Gouaux, 2011.)1  
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Results 
L9’ mutations increase glutamate sensitivity 
The highly conserved leucine 9’ residue in the M2 domain of the α subunit was mutated 
to each of seven other residues, L9’I, F, V, A, G, S, T. The heteromeric GluCl αβ wild-
type (WT), fluorescently tagged (WT-XFP), and L9’ mutant channels (also -XFP tagged) 
were expressed in HEK293 cells and examined for glutamate sensitivity using the 
millisecond microperfusion capability of the Dynaflow Pro II chip. Whole-cell 
concentration-response relations were obtained. Each patched cell was exposed to at least 
seven glutamate concentrations applied in increasing order. One-second glutamate 
applications induced fast-activating current responses followed by complete ligand 
washout upon bath solution postapplication (Figure 3-2A). Currents were activated in a 
concentration-dependent manner. Normalized concentration-response curves and Hill fit 
parameters are shown in Figure 3-2B and Table 3-1. A saturating dose was unable to be 
applied in some cases, as pre-exposure of glutamate, which accumulates in the cell 
reservoir from the lanes of laminar flow over time, appeared to desensitize receptors 
leading to reduced or undetected current responses. Response normalization to a less-
than-saturating concentration, as is the case for the WT and L9’G mutant receptors, leads 
to an overestimation of glutamate sensitivity (i.e., a lower, inaccurate estimation of EC50). 
All other L9’ mutations significantly increased glutamate sensitivity by a factor of 5- to 
90-fold, as determined by EC50, compared to the WT-XFP receptor (Figures 3-2C; Table 
3-1). Maximum current responses for the L9’ mutant channels, however, were 
significantly reduced (Figure 3-2D).  In addition, many cells expressing L9’ mutant 
channels revealed a large holding current prior to application of glutamate, which was 
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often predictable by a lack of capacitive transients in whole-cell configuration. Such 
observations are characteristic of membrane leakiness, presuming the cells maintained 
seal resistance and were not sick or dead. Leak currents are likely due to an increased 
probability of unliganded channel openings resulting from the L9’ mutation. 
 
	  
	  
Figure 3-2.  Glutamate activation of heteromeric GluCl αβ  wild-type (WT), fluorescently tagged 
(WT-XFP), and L9’ mutant channels.  A. Whole-cell patch clamp recording of glutamate-induced current 
from the WT receptor expressed in HEK293 cells. Black bars indicate 1-second applications of 5, 10, 20, 
50, 100, 200, and 500 µM glutamate.  B. Glutamate concentration-response curves fit with the Hill 
equation.  C. All 9’ mutant channels except L9’G significantly increased glutamate sensitivity.  D. 
Maximum induced current (Imax) from glutamate activation. Current magnitudes are represented as negative 
values.    
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Table 3-1.  Glutamate activation parameters of GluCl WT, WT-XFP, and L9’ mutant channels.  
Parameters correspond to concentration-response curves in Figure 3-2B. The EC50 and Hill coefficient 
values represent the mean ± SEM for the number of cells (n) recorded. The * indicates response 
normalization to a less-than-saturating maximum concentration.  
 
Functional studies of GluCl receptors expressed in Xenopus laevis oocytes using 
two-electrode voltage clamp have demonstrated that homomeric channels of both α and β 
subunits are functional, but they exhibit contrasting agonist activation profiles. 
Homomeric GluCl α channels are activated directly by IVM, but not glutamate, while 
homomeric GluCl β channels are activated directly by glutamate, but not IVM25.  It has 
since been determined that α homomers do in fact maintain glutamate binding sites, but 
are deficient in coupling glutamate binding events to channel gating1,26. In the present 
study, no glutamate-induced currents were recorded from HEK293 cells transfected with 
GluCl β(WT) cDNA only, probably because homomeric GluCl β channels are not 
expressed at the plasma membrane. Discrepancies in surface expression between 
mammalian systems and oocytes have been observed for other membrane proteins and 
are assumed to be the result of different protein trafficking mechanisms27-30. The 
GluCl channel abbr. EC50  (µM) Hill n 
!(WT) + "(WT) WT 314 ± 133* 1.28 ± 0.23 14 
!-YFP + "-CFP WT-XFP 132 ± 5 1.64 ± 0.07 12 
"(WT) homomer NR 
!-YFP L9’V homomer NR 
!-YFP L9’I + "-CFP L9’I   3.0 ± 0.4 1.13 ± 0.23 6 
!-YFP L9’F + "-CFP L9’F 17.0 ± 1.8 1.75 ± 0.27 10 
!-YFP L9’V + "-CFP L9’V   1.4 ± 0.1 1.18 ± 0.11 8 
!-YFP L9’A + "-CFP L9’A 17.7 ± 1.6 1.79 ± 0.24 6 
!-YFP L9’G + "-CFP L9’G 91.8 ± 17.1* 1.34 ± 0.14 9 
!-YFP L9’S + "-CFP L9’S 24.9 ± 1.7 1.84 ± 0.17 14 
!-YFP L9’T + "-CFP L9’T   3.8 ± 0.6 1.32 ± 0.18 12 
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possibility that presence of an L9’ mutation now allowed GluCl α homomers to be gated 
by glutamate was also considered. No currents were recorded from the L9’V α homomer 
for the glutamate concentrations applied (≤ 500 µM).   
Whole-cell glutamate concentration-response relations for a given receptor were 
subject to a great deal of cell-to-cell variability. Different cells recorded on the same day, 
from the same culture dish, using the same glutamate solutions, displayed very different 
concentration-dependent responses, even for the WT receptor (Figure 3-3A). 
Desensitization kinetics also varied greatly from cell-to-cell. To examine this variability, 
concentration-response curves for individual cells were compared. Individual response 
curves could be separated into distinct categories based on sensitivity (Figure 3-3B, Table 
3-2). This wide range in agonist sensitivity was evident with all L9’ mutants except for 
L9’F (Figure 3-3C, Table 3-2). Typically, heteromeric receptor expression that gives rise 
to multiple agonist sensitivities is due to the presence of different stoichiometric 
populations which result in biphasic concentration-response relations31-33. It is assumed 
that an individual cell would express some fraction of each receptor stoichiometry. 
Interestingly, for GluCl, most individual cells display a monophasic concentration-
response relationship. It is unclear whether the various glutamate sensitivities are due to 
stoichiometric preferences or some other inherent inconsistencies (e.g., cross-
contamination, phenotypic diversity) within HEK293 cell cultures34,35. 
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Figure 3-3.  Cell-to-cell variability of glutamate concentration-response relations.  A. Cells expressing 
GluCl WT receptor recorded on the same day, from the same culture dish, responded differently to 
application of the same glutamate solutions (see Figure 3-2 for concentrations).  B. Concentration response 
curves of individual cells could be separated into three categories: high sensitivity (red line), low sensitivity 
(blue line), and mixed (green line).  C. Cell-to-cell variability was observed for nearly all mutant receptors 
tested. 
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Table 3-2.  Variability in glutamate activation parameters for heteromeric GluCl αβ  WT, WT-XFP, 
and L9’ mutant channels. Parameters correspond to concentration-response curves in Figure 3-3B, C. The 
EC50 and Hill coefficient values represent the mean ± SEM for the number of cells (n) recorded. The * 
indicates response normalization to a less-than-saturating maximum concentration.   
 
L9’ mutational effect on EC50 correlates with alpha-helical destabilization 
Studies involving the cation-selective Cys-loop receptors suggest the magnitude of 
increased agonist sensitivity was influenced by the polarity of the L9’ mutation8,10,11. To 
check for a correlation between the identity of the amino acid mutation and the 
magnitude of increased agonist sensitivity, the log(EC50) value of each L9’ mutant 
channel was plotted against several physical properties of the amino acid side-chain, 
including hydrophobicity36, surface area37, and propensity towards α-helix stabilization38. 
GluCl L9’ mutations show no functional relationship dependent on side-chain 
hydrophobicity or side-chain surface area (Figure 3-4A, B). A potential trend in surface 
area is negated by the fact that Leu and Ile have nearly the same surface area (180 Å2 vs. 
182 Å2) but give very different EC50 values. There does appear to be a correlation 
between the identity of the L9’ mutant side-chain and its effect on α-helix stabilization 
(Figure 3-4C). Excluding the two extremes of Ala, the amino acid with the highest helical 
High Sensitivity Mixed Low Sensitivity 
EC50  (µM) Hill n EC50  (µM) Hill n EC50  (µM) Hill n 
WT 44.71 ± 0.00 3.05 ± 0.17 1 159.65 ± 0.01 2.03 ± 0.12 9 2564.9 ± 3.98* 1.45 ± 0.15 4 
WT-XFP 80.68 ± 0.00 2.22 ± 0.13 6 145.91 ± 0.02 1.49 ± 0.16 3 306.90 ± 0.01* 2.41 ± 0.09 3 
!L9’I 1.80 ± 0.00* 1.91 ± 0.67 3 10.57 ± 0.00 1.08 ± 0.12 3 
!L9’F 17.25 ± 0.00 1.75 ± 0.17 10 
!L9’V 1.22 ± 0.00 1.34 ± 0.15 7 9.95 ± 0.00 1.17 ± 0.11 1 
!L9’A 9.99 ± 0.00 2.25 ± 0.30 4 24.04 ± 0.00 2.13 ± 0.25 2 
!L9’G 74.14 ± 0.02 1.26 ± 0.16 5 108.86 ± 0.02* 1.54 ± 0.16 4 
!L9’S 17.76 ± 0.00 2.29 ± 0.34 9 58.13 ± 0.00 1.67 ± 0.11 5 
!L9’T 1.19 ± 0.00* 1.81 ± 0.39 3 3.91 ± 0.00 1.48 ± 0.16 7 500.12 ± 2.48* 0.92 ± 0.11 2 
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propensity39,40, and Gly, which is given a value of zero on most scales as it lacks a 
contributing side-chain, the energy values associated with disrupting the stability of the 
pore-lining α-helix do trend with the shifts in EC50. The less stable the helix (higher 
energy), the more sensitive the receptor is to glutamate (lower EC50). The three β-
branched amino acids, Ile, Val, and Thr, give the largest gain-of-function shifts in EC50 
for the L9’ mutant channels. β-branched amino acids are known to destabilize an α-helix 
due to a loss of side chain conformational entropy41-43. Specifically, the rotational 
freedom of a β-branched side-chain is restricted by steric hindrance, in that substituents 
in a γ-position of the side chain interfere with the carbonyl oxygen atoms of the residues i 
– 2 and i – 3 in the helix. Overall, destabilization of the M2 pore-lining α-helix at the L9’ 
position may lower the energy barrier for the closed-to-open conformational change 
making it easier for the channel to open in the presence of agonist.  
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Figure 3-4.  Functional relationships of L9’ mutant channels with physical properties of amino acid 
mutation.  A & B. The L9’ gain-of-function effect is not dependent on side-chain hydrophobicity or side-
chain surface area.  C. The L9’ gain-of-function effect does correlate with side-chain disruption of an α-
helical conformation. Ala and Gly residues are considered outliers. Line represents a linear regression fit of 
the seven other data points. Two data points for Leu represent those for the WT and WT-XFP receptors.  
 
L9’ mutations increase background conductance 
Destabilization of the pore-lining helix may also be responsible for the large holding 
currents and lack of whole-cell transients observed prior to glutamate application. A more 
flexible gate could increase the probability of spontaneous channel openings which 
would contribute to the background conductance of a cell at rest. The presence of 
spontaneous channel activity is often confirmed by the use of open-channel blockers in 
the absence of agonist. Picrotoxin and fipronil sulfone are known pore blockers of 
GluCl44,45. However, they have both been reported to exhibit differential blocking effects 
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on the desensitizing and nondesensitizing components of glutamate evoked currents, 
presumably due to differences in subunit stoichiometry46-49. It has also been demonstrated 
in several studies that the typical blocking mechanism of picrotoxin is impaired with both 
agonist activated and spontaneously open receptors bearing L9’ mutations9,16,21. 
Therefore, the use of pore blockers is not practical for assaying the amount of 
background conductance for the various GluCl L9’ mutant channels. Instead, a voltage 
ramp protocol was adopted50.  
Cells were voltage clamped in whole-cell configuration with no capacitive 
compensation. The voltage was ramped continuously from −60 mV to +60 mV over 50 
ms in the absence of ligand. An example of a WT current response is shown in Figure 3-
5A. The background conductance was measured from the slope of the resistive current 
ramp and normalized by the mean membrane capacitance of each receptor, which could 
be calculated from the capacitive current offset. Because it can be difficult to distinguish 
between cells with a leaky membrane and patches with a poor seal, cells with a seal 
resistance less than 40 MΩ, corresponding to a chord conductance of > 25 nS, were 
omitted. GluCl WT and WT-XFP receptors show minimal background conductance that 
is not different from a mock-transfected control (Figure 3-5B). The two L9’ mutations 
with the smallest side-chains, L9’A and L9’G, had the largest background conductance 
which was significantly different from WT receptors. Notably, these are the same two 
L9’ mutants that were not in accordance with the disruption of α-helical stability 
correlation. The three L9’ mutants with β-branched side-chains did have a greater 
background conductance than WT receptors on average, but the increase was not 
statistically significant for the number of cells sampled. 
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Figure 3-5.  Background conductance of GluCl receptors in absence of ligand.  A. Example of a current 
response from GluCl WT. Whole-cell voltage-clamped cells with no capacitive compensation were ramped 
from −60 mV to +60 mV over 50 ms. The total current across the membrane Im is the sum of the capacitive 
current Ic, and the resistive current, IR.  B. Background conductance normalized by the mean capacitance of 
each receptor for the number of cells recorded (shown in parentheses). Soluble GFP was used as a mock-
transfection control.  
 
The L9’ gain-of-function effect is maintained for IVM 
It was unknown whether an L9’ mutation would maintain a gain-of-function gating effect 
for an agonist that activates the channel through a different allosteric mechanism (e.g., 
IVM) than that triggered by a typical neurotransmitter binding event (e.g., glutamate). 
Assaying channel function with IVM by electrophysiology, however, is challenging.  
IVM is a lipophilic compound with limited ligand washout, making it difficult to apply 
successive doses to an individual cell which is necessary for concentration-response 
normalization. To circumvent this, L9’ mutant receptor activation was measured by a 
fluorescence-based assay using a membrane potential-sensitive dye. 
Glutamate activation and IVM activation were first measured individually for 
GluCl WT channels. Even with this indirect functional assay, different response kinetics 
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were apparent for the two agonists, resembling the differences observed in their direct 
electrophysiological response25. Specifically, the raw signal (in relative fluorescence 
units, RFU) induced by glutamate reaches a maximum within 3 min, followed by a 
decline for nonsaturating concentrations. The IVM-induced signal is slower to rise but 
remains at maximum for up to 5 min (Figure 3-6A). Both glutamate and IVM generated 
fluorescent signals for GluCl WT and WT-XFP receptors in a concentration-dependent 
manner (Figure 3-6B). All L9’ mutants, except for L9’F, displayed a much weaker signal 
for both glutamate and IVM activation (Figure 3-6C). The reduced signal results from 
elevated baseline fluorescence (Figure 3-6D) which is likely a reflection of the increased 
background conductance observed for these mutants. Normalization of the raw RFU 
signal indicates that the L9’F mutation increases receptor sensitivity to both glutamate 
and IVM compared to WT and WT-XFP receptors (Figure 3-6E). Glutamate activation 
parameters are comparable to those obtained by electrophysiology (Table 3-3). IVM 
activation parameters reveal that WT-XFP receptors do not have the same concentration-
dependent relationship as WT receptors, and the L9’F mutant receptor displays a biphasic 
concentration-dependent response.  
Homomeric channels were assayed once more for agonist activation using the 
membrane potential dye. As expected, GluCl α(WT) homomers were not activated by 
glutamate. GluCl α(WT) homomers were, however, responsive to IVM (Figure 3-7). This 
was unexpected as previous studies report that no current was obtained from mammalian 
cells when the α subunit was expressed alone23,51. GluCl α-XFP homomers, as well as 
those containing the L9’F mutation were also responsive, producing much steeper and 
right-shifted concentration-response curves for IVM (Table 3-4). Removal of the XFP tag 
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from the L9’F mutant channel did not recover IVM sensitivity. This implies two things: 
(1) that the XFP insertion is having some functional effect on GluCl activation by IVM 
that was not apparent with glutamate, and (2) that incorporation of the β subunit is 
necessary for the increased IVM sensitivity observed with the heteromeric GluCl L9’F 
mutant. GluCl β(WT) homomers did not respond to glutamate or IVM applications.  
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Figure 3-6.  Heteromeric GluCl αβ  WT, WT-XFP, and L9’ mutant receptor activation measured by 
a fluorescent membrane potential-sensitive dye. (Left panel: glutamate activation; Right panel: IVM 
activation) A. Example of raw RFU signal for GluCl WT (8 of 15 responses shown).  B. RFU signals for 
GluCl WT and WT-XFP are concentration-dependent. Nontransfected cells do not respond to agonist.  C & 
D. All L9’ mutants receptors, except for L9’F, show diminished agonist-induced RFU signals and elevated 
baseline RFU signals.  E. Normalized concentration-response curves for GluCl WT, WT-XFP, and L9’F 
mutant receptors. The concentration-response relation for IVM activation of the L9’F mutant was best fit 
by the sum of two Hill equations.  
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Table 3-3.  Activation parameters acquired with the membrane potential assay for heteromeric 
GluCl αβ  WT, WT-XFP, and L9’F mutant channels. Parameters correspond to concentration-response 
curves in Figure 3-6E. The EC50 and Hill coefficient values represent the mean ± SEM for six 
measurements. The high sensitivity component of the biphasic L9’F curve corresponds to 61% of the 
normalized response. 
 
	  
Figure 3-7.  Ivermectin activation of homomeric GluCl α  WT, WT-XFP, and L9’F mutant channels. 
Normalized concentration-response curves were fit with the Hill equation.      
   
 
	  
Table 3-4.  Ivermectin activation parameters for homomeric GluCl α  WT, WT-XFP, and L9’F 
mutant channels. Parameters correspond to concentration-response curves in Figure 3-7. The EC50 and 
Hill coefficient values represent the mean ± SEM for six measurements. 
Glu activation IVM activation 
GluCl channel EC50  (µM) Hill EC50  (!M) Hill 
!(WT) + "(WT) 349.00 ± 44.29 1.40 ± 0.18 138.45 ± 9.60 1.04 ± 0.06 
!-YFP + "-YFP 455.80 ± 53.14 1.62 ± 0.23 342.64 ± 31.52 2.41 ± 0.39 
!-YFP L9’F + "-YFP 63.07 ± 7.12 1.55 ± 0.24 7.27 ± 2.85    (61%) 1.14 ± 0.24 
185.35 ± 50.16 1.99 ± 0.82 
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IVM activation 
GluCl channel EC50  (!M) Hill 
!(WT) homomer 285.51 ± 75.17 1.01 ± 0.15 
!-YFP homomer 406.88 ± 21.08 2.47 ± 0.24 
!-YFP L9’F homomer 472.67 ± 44.23 1.64 ± 0.19 
! L9’F homomer 492.99 ± 95.91 1.07 ± 0.20 
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Discussion 
L9’ effects 
Mutational effects of L9’ have varied across the family of Cys-loop receptors and are 
dependent on the physical properties of the amino acid being introduced. Even the 
slightest differences are likely to have big functional consequences in such a critical 
region of the channel. For GluCl, six of seven L9’ mutations significantly increased 
glutamate sensitivity, and not all of the L9’ mutants show increased spontaneous activity. 
This is the first report of a correlation between pore-lining helix stability and agonist 
sensitivity. According to the Monod-Wyman-Changeux (MWC) model of allosteric 
activation52, channel gating (i.e., events that enable the closed-to-open state transitions) 
involves global conformational changes within and across subunits. Destabilization of the 
M2 α-helix by β-branched amino acids may lower the energy barrier for a closed-to-open 
conformational change making it easier for the channel to open both in the presence 
(apparent from the left-shifted EC50) and absence (apparent from the increased 
background conductance) of agonist. However, the L9’A mutant, which should form the 
most stable pore-lining helix, actually shows the greatest increase in background 
conductance. It may be that the 9’ position requires a large, hydrophobic, non-β-branched 
side-chain to stabilize the closed state conformation. Whether or not the L9’ residue 
prevents ion flow by physically occluding the channel pore cannot be determined from 
this study. 
Variability from cell-to-cell during the electrophysiology experiments made it 
difficult to draw conclusions about any L9’ mutational effects on receptor desensitization. 
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In general, it appeared that high sensitivity glutamate responses for all receptors showed 
more desensitization. This may also be reflected in the raw glutamate-induced signals of 
the membrane potential assays (Figure 3-6A, left panel). For example, signal responses 
for low concentrations, which would activate high sensitivity channels, show a decline 
after the first minute of glutamate application. As higher concentrations are applied low 
sensitivity channels, which do not desensitize, would become activated so the signal no 
longer declines over time.  
 
Stoichiometry 
There is some evidence for the co-existence of two pharmacologically distinct and 
physiologically relevant GluCl channels. Invertebrate neuron recordings display 
glutamate-induced currents comprised of variable fractions of desensitizing and non-
desensitizing components, which were blocked differentially by picrotoxin and fipronil 
sulfone46-49. These differential pore-blocking effects may be explained by a subunit 
specific dependence of blockade44, suggesting the presence of more than one GluCl 
stoichiometry. 
The biphasic IVM concentration-response curve of the L9’F mutant in the 
membrane potential assay supports a mixed stoichiometry hypothesis. The glutamate 
concentration-response relation obtained for this mutant, however, is monophasic. 
Furthermore, the L9’F mutant was the only receptor that did not show variation in 
glutamate sensitivity during whole-cell patch-camp recordings. It is possible the 10 cells 
patched were not representative of the entire transiently transfected cell population. 
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While patch-clamp experiments directly sample individual cells, sample sets are small 
and can be biased by cell selection and sealing success of the experimenter. The 
membrane potential assay, on the other hand, is a population measurement. Any cell-to-
cell variability is coalesced into a single composite response. 
With expression of GluCl in HEK293 cells, glutamate activated currents are most 
likely conducted by heteromeric receptors, since β homomers are probably not expressed 
at the cell surface and α homomers are not directly gated by glutamate. It is conceivable 
that different receptor stoichiometries do not differ significantly in glutamate sensitivity, 
resulting in a concentration-dependence that is uninterrupted. The biphasic heteromeric 
and monophasic homomeric concentration-response curves for the L9’F mutant indicate 
that incorporation of the β subunit significantly increases IVM sensitivity. The precise 
stoichiometric ratio of α:β subunits cannot be determined from this functional study. It 
should also be noted that the number of bound IVM molecules required to gate the 
channel is unknown. It cannot be ruled out that the number of agonists bound could 
influence the biphasic concentration response.  
Studies employing L9’ mutations in all five subunits have shown that the extent 
of increased agonist sensitivity was dependent on the number of subunits containing L9’ 
substitutions, i.e., the magnitude of EC50 shifts were additive5,6,9,53. It was consequently 
inferred that each subunit provides independent and equivalent contributions to channel 
gating. More detailed analysis of this mutagenesis data found that L9’ effects of 
individual subunits are not identical, rather, the various subunits bearing L9’ mutations 
contribute unequally to channel gating10,14,18,20,53. The gain-of-function effect of an L9’ 
mutation appears to be influenced by the structurally asymmetric pore of a heteromeric 
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channel compared to the perfectly symmetrical pore geometry of homomers. The 
influence of asymmetry is especially apparent in the present study, as heteromeric 
channels bear L9’ mutations only in the α subunit; the β subunit still contains Leu at this 
position. A ring of five L9’F mutations as in the α homomer does not increase sensitivity 
to IVM. Differences in constitutive activity between heteromeric and homomeric 
receptors have also been reported20.  
 
FlexStation assay limitations 
In the membrane potential assay, the voltage sensitive dye partitions across the cell 
membrane depending on the resting membrane potential of the cell. Dye quenchers are 
present in the extracellular solution. Upon stimulus, the dye follows movement of 
positively charged ions, so membrane depolarization allows the dye to enter the cell 
where it is dequenched resulting in a positive fluorescent signal.  Conversely, during 
hyperpolarization, dye is requenched as it exits the cell resulting in a negative fluorescent 
signal. The positive fluorescent signal observed in the present study following induction 
of Cl− currents therefore seems counterintuitive. A similar result, however, has been 
observed and eloquently discussed for HEK293 cells expressing GlyR54. In short, as an 
embryonic cell line, HEK293 cells have a relatively high intracellular chloride 
concentration compared to other mammalian cells, so channel opening allows efflux, 
rather than influx, of Cl− current thereby decreasing the separation of charge and resulting 
in depolarization of the membrane. Elevated basal levels of fluorescence and negligible 
agonist-induced responses were observed in a related GlyR study with receptors 
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containing other M2 domain mutations55. The authors propose constitutive activation as a 
possible explanation. The present study confirms that receptors with increased levels of 
spontaneous activity do show elevated basal signals and diminished responses to agonist 
application in a membrane potential assay. An increased background conductance likely 
affects distribution of the dye during the incubation period. The amount of de-quenched 
dye that has already entered the cell is high, so the amount of additional dye moving into 
the cell upon application of agonist is low. Since the assay only measures changes in 
membrane potential rather than inherent values, a diminished signal is observed. 
 
L9’F as an optimized silencer 
We have previously demonstrated that an engineered GluCl channel can be used to 
selectively silence electrical activity in targeted CNS neurons in vivo when activated by 
IVM. Both α and β subunits were necessary in order to achieve silencing. GluCl α 
homomers were reportedly not expressed. This study shows that α homomers are indeed 
expressed and that α-XFP homomers require greater concentrations of IVM for 
activation. Introduction of an L9’F mutation may promote β subunit incorporation as a 
method of increasing IVM sensitivity. Unlike other mutants, L9’F substantially increased 
agonist sensitivity without increasing background conductance, a fundamental 
requirement as spontaneous openings would be detrimental to the goal of a 
pharmacologically induced silencer. While all L9’ mutants reduced the maximum 
glutamate response of patch-clamped cells, the fluorescent signal generated by L9’F 
mutants in the membrane potential assay was not diminished compared to WT receptors. 
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Nevertheless, HEK293 cells generally produce massive currents, so it is conceivable that 
the L9’F mutant receptor would conduct sufficient Cl− current to silence a neuron. 
Altogether, introduction of an L9’F mutation may enhance the GluCl/IVM silencing tool. 
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Materials and Methods 
Site-Directed Mutagenesis 
Previously described plasmid vector pcDNA3.1/V5-His TOPO (Invitrogen #K4800-01) 
containing the complete optimized coding sequence for either unlabeled or fluorescently 
tagged Caenorhabditis elegans GluCl α and β subunits, namely optGluCl αWT, 
optGluCl βWT, optGluCl α-YFP, and optGluCl β-YFP56, were used in this study. Note, 
‘opt’ has been removed from the nomenclature in this text. Enhanced yellow fluorescent 
protein (YFP) insertions are located within the intracellular M3-M4 loop24. Leucine 9’ 
mutations were made using the QuikChange II XL site-directed mutagenesis kit (Agilent 
Technologies #200522) with PfuTurbo DNA polymerase (Agilent Technologies 
#600250) using the following forward and reverse primers: 5’ – CC CTG GGC GTG 
ACC ACC CTG xxx AC – 3’ and 5’ – GC GGA CTG AGC GGT CAT GGT xxx CA – 
3’, where ‘xxx’ delineates the mutated Leu9’ codon. Leu9’ mutations included Ile, Phe, 
Val, Ser, Thr, Ala, and Gly. All mutations were confirmed by DNA sequencing. 
 
Cell Culture 
Human embryonic kidney (HEK) 293 cells were purchased from ATCC (#CRL-1573). 
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco #11965) 
supplemented with 10% FBS (Gibco #26140), 100 units/ml penicillin, 100 µg/ml 
streptomycin (Gibco #15140), and 1 mM sodium pyruvate (Gibco #11360), and 
maintained at 37°C and 5% CO2 in a humidified incubator. Cells were passaged when 
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confluent at a subcultivation ratio of 1:5 or 1:10 every 3 to 4 days. For electrophysiology 
experiments, HEK293 cells were plated at a density of 150,000 cells/dish in 35 mm 
culture dishes. GluCl receptors were expressed via transient transfection for which 1 µg 
DNA in 100 µl DMEM was combined with 4 µl ExpressFect (Denville Scientific 
#E2650) in 100 µl DMEM that was pre-incubated for 20 minutes before adding to culture 
dishes containing 2 ml fresh culture medium. For FlexStation assays, HEK293 cells were 
plated at 20,000 cells/well, with a plating volume of 100 µl/well, in a black-sided/clear-
bottomed 96-well imaging plate (BD Falcon #353219). For transfection, 16 µg total DNA 
in 750 µl DMEM was mixed with 30 µl ExpressFect in 750 µl DMEM, pre-incubated for 
20 minutes, and then added at 15 µl/well to cells containing 100 µl fresh culture media. 
For both electrophysiology and FlexStation assays, cells were transfected 24 hours after 
plating and assayed 48 hours after transfection. Transfection mixes were removed from 
cultures following a 4–6 hour incubation period at 37°C/5% CO2 and replaced with fresh 
culture medium.  
 
Electrophysiology 
Whole-cell patch-clamp recordings were obtained using an Axopatch 200A amplifier 
with a CV201 headstage and Digidata 1200 series interface (Axon Instruments). A Hum 
Bug device (Quest Scientific) was used to eliminate 50/60 Hz noise. Data was acquired 
using Clampex 9.2 software (Axon Instruments). Dose-response data was recorded at a 
sampling frequency of 5 kHz with lowpass filtering at 1 kHz in Gap-free acquisition 
mode. Voltage ramp data was sampled at 10 kHz with lowpass filtering at 5 kHz in 
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Episodic Stimulation acquisition mode. External bath recording solution contained (in 
mM): 140 NaCl, 2.8 KCl, 2 CaCl2, 2 MgCl2, 10 D-glucose, 10 HEPES, 5 NaOH, pH 
7.35, 330 mOsm.  Internal patch pipette solution contained (in mM):  130 CsCl, 4 MgCl2, 
4 Na2-ATP, 1 EGTA, 10 HEPES, 10 CsOH, pH 7.35, 315 mOsm. Pipettes were made 
from borosilicate glass with resistances of 4–10 MΩ. Co-transfection of soluble 
pmaxGFP (Amaxa) was used to identify transfected HEK293 cells. Cells were voltage-
clamped with a holding potential of −60 mV. All recordings were performed at ambient 
temperature. 
Glutamate concentration-response experiments were conducted using the 
Dynaflow Pro II system, a millisecond microperfusion chip (Cellectricon). GluCl-
expressing HEK293 cells initially plated in 35 mm plastic culture dishes were washed 
with bath solution, detached using a cell scraper, and declumped by trituration to produce 
a 500 µl volume of round cells in suspension. Cells were added 100 µl at a time to 2 ml 
fresh bath solution intermittently to avoid lengthy pre-exposure to glutamate due to 
accumulation from the lanes of laminar flow into the cell reservoir. Na+ glutamate (Sigma 
#G1626) was dissolved in water as a 100 mM stock and stored as 1 ml aliquots at -20°C. 
Glutamate concentrations, prepared as serial dilutions in bath solution, were applied in 
increasing order for 1 second each, alternating with 1 second applications of external bath 
solution for complete ligand washout.  
A continuous voltage ramp protocol was used to measure background 
conductance in the absence of ligand. Cells were whole-cell voltage-clamped at −60 mV 
with no capacitive compensation then ramped from −60 mV to +60 mV over 50 ms. 
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Membrane Potential Measurements 
A fluorescence-based assay employing the FLIPR Membrane Potential Assay Kit, BLUE 
formulation, (Molecular Devices, #R8042) was used to detect voltage changes across the 
cell membrane. The dye reagent is of proprietary composition57. Dye loading buffer was 
prepared according to package literature. Specifically, the contents of one vial of BLUE 
reagent was dissolved with 5 ml of 1x Assay Buffer, followed by a wash of the vial with 
another 5 ml of 1x Assay Buffer, to yield a total volume of 10 ml of dye loading buffer. 
Unused portions of dye loading buffer were stored at -20°C and used within 5 days. For 
the functional assay, culture medium was removed from the cells and replaced with 50 µl 
DMEM.  Cells were then loaded with 50 µl of Blue dye loading buffer and incubated for 
40 min at 37°C/5% CO2. The signal was detected using the FlexStation 3 multimode 
benchtop microplate reader operated by SoftMax Pro Data Acquisition & Analysis 
Software (Molecular Devices). Excitation and emission wavelengths were set at 530 nm 
and 565 nm, respectively, with an emission cut-off of 550 nm. Plate reads were 
performed at ambient temperature with a ‘Low PMT’ setting. Run times, of which the 
first 20 s measured basal fluorescence, were 180 s for glutamate-induced signals or 300 s 
for ivermectin-induced signals. Other FlexStation parameters included a pipette height of 
230 µl, an initial well volume of 100 µl, a transfer volume of 50 µl (therefore, drug 
concentrations were prepared 3x), and a transfer rate setting of 2, corresponding to ~31 
µl/sec. Glutamate concentrations were prepared from 100 mM aliquots as 1:10 serial 
dilutions of 5, 2, and 1 mM dissolved in a 1x commercial stock of Hanks’ balanced salt 
solution (HBSS, without phenol red; Invitrogen #14025) with 20 mM HEPES, pre-
adjusted to pH 7.4 with sodium hydroxide. Ivermectin (Sigma #18898) was dissolved in 
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DMSO as a 10 mM stock and stored as 0.3 mM aliquots at -20°C. Ivermectin 
concentrations for the FlexStation assay were prepared as 1:10 serial dilutions of 10, 5, 
and 2 µM using 1x HBSS with 20 mM HEPES at pH 7.4, containing 0.1% DMSO. 
 
Data Analysis 
Electrophysiology data was analyzed using Clampfit 9.2 software. Glutamate-induced 
currents were normalized for each cell individually by the maximal current response for 
that cell. Concentration-response curves were constructed and fit to the following 
sigmoid Hill function in Origin 7.0 (OriginLab),  
 
which can be rewritten as,  
 
where I is the amount of current induced by a given agonist concentration [A], Imax is the 
maximum current induced, EC50 is the concentration required to elicit half the maximal 
response and H is the Hill coefficient.  
 For voltage ramp experiments, the total current, Im, can be broken down as the sum 
of the capacitive current, IC, and the resistive current, IR, across the membrane (Im = IC + 
IR). Background conductance, G, was measured from the slope of the resistive current 
ramp (G = dIR/dV). Membrane capacitance, Cm, was calculated by measuring the 
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capacitive current from the offset of the current ramp (IC = Cm(dV/dt)). The background 
conductance was then normalized by the mean capacitance for each receptor and plotted 
as mean ± SEM from 12 or more cells. To distinguish a large background conductance 
from poor sealing of the patch pipette, cells with a seal resistance of < 40 MΩ, 
corresponding to a chord conductance of > 25 nS (as determined by G = I/V = 1/R), were 
omitted.  
Raw FlexStation signals were exported as ‘.txt’ files from SoftMax Pro 5 and 
analyzed offline using Microsoft Excel 2008 and Origin 7.0. Relative fluorescent unit 
signals were zeroed by mean subtraction of the first 5 data points, then smoothed using a 
3-point sliding average before determining the maximum data point per well. Six, 15-
point concentration-response data sets were obtained from a single 96-well plate, set up 
as 2 columns of 8 wells including a blank, repeated 5 more times in subsequent columns. 
Signals of each well were normalized by the maximum signal for that particular 2-
column set to compensate for signal run-down over time. Normalized data was then 
averaged to construct concentration-response curves as described above.  
 
Statistics 
Pooled data for each mutation are shown as means ± SEM. Boxplots represent the mean, 
median, 25th, and 75th percentiles. Statistical significance (P < 0.05) was determined by 
one-way analysis of variance (ANOVA) on ranks using multiple pairwise comparison. 
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Chapter 4 
 
GluClv2.0: An Improved Tool For Neuronal Silencing 
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Abstract 
A variety of genetically encoded tools have been developed that allow physical 
manipulation of neuronal excitability in a reversible, cell-specific manner. We previously 
engineered an invertebrate glutamate-gated chloride channel (GluCl αβ) that enabled 
pharmacologically induced silencing of electrical activity in targeted CNS neurons in 
vivo by the anthelmintic drug compound ivermectin (IVM). With this receptor, GluCl opt 
α-CFP + opt β-YFP Y182F, the concentration of IVM necessary to elicit a consistent 
silencing phenotype was high enough to raise concern about its potential side effects. 
Variability in the extent of spike suppression was also apparent and correlated with co-
expression levels of the fluorescently tagged α and β subunits. To address these issues, 
mutant receptors were generated via rational protein engineering strategies and subjected 
to functional screening and fluorescence-based assays. It has since been learned that 
GluCl α homomers are indeed expressed at the plasma membrane and are responsive to 
IVM, but incorporation of the β subunit confers greater IVM sensitivity. Introduction of a 
gain-of-function mutation (L9’F) in the second transmembrane domain of the α subunit 
appears to facilitate β subunit incorporation and substantially increase heteromeric GluCl 
αβ sensitivity to IVM without permitting unliganded channel opening. Removal of an 
arginine-based ER retention motif (RSR mutated to AAA) from the intracellular loop of 
the β subunit further promotes heteromeric expression at the plasma membrane by 
preventing ER-associated degradation of the β subunit. Introduction of a monomeric XFP 
mutation (A206K) complements these effects. The newly engineered GluCl opt α-mXFP 
L9’F + opt β-mXFP Y182F RSR_AAA receptor significantly increases conductance and 
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reduces variability in evoked spike generation in vitro using a lower concentration of 
IVM. This receptor, dubbed ‘GluClv2.0’, is an improved tool for IVM-induced silencing. 
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Introduction 
Neurons are organized into anatomically distinct regions that transmit excitatory or 
inhibitory information to the regions they project to, following a specific pathway or 
circuit. Inappropriate activity within such a circuit is thought to be the basis of most 
psychiatric and neurological disorders. Unraveling the intricate circuitry and functional 
basis of various neuronal networks will provide a better understanding of complex 
behavior and help pinpoint the underlying causes of brain related dysfunction.  
A number of tools have been developed that allow the physical manipulation of 
neuronal excitability in a reversible, cell-specific manner. These tools enable mapping of 
neuronal connectivity and are essential for assigning functional roles to particular cell 
types and determining their contribution to perception or behavior. One such tool 
employs a heteromeric glutamate-gated chloride channel (GluCl αβ) from the 
invertebrate species Caenorhabditis elegans and the anthelmintic drug compound 
ivermectin (IVM). IVM-induced activation of GluCl αβ heterologously expressed in 
mammalian neurons elicits a chloride conductance that drives the membrane potential 
toward the Nernst potential of chloride (ECl) to prevent action potential generation for 
effective neuronal silencing.  
The GluCl/IVM method was the first to show neuronal silencing induced by a 
systemically administered drug in awake, behaving animals1. In this study, proof-of-
concept was demonstrated in mice using a robust and reproducible striatal lesion assay 
known to induce amphetamine-dependent rotational behavior2,3. In mice expressing 
GluCl unilaterally in the striatum via AAV2-mediated infection, systemic administration 
	   84	  
of IVM caused unidirectional rotation of the animal, indicating that striatal neurons were 
silenced (Figure 4-1A). The rotational phenotype was observed within hours of induction 
and was fully reversed within days, allowing multiple cycles of silencing and recovery to 
be performed on a single animal.  
IVM is a widely used commercial drug that is well tolerated by both animals and 
humans because GluCl channels do not exist in mammals. Selective and reversible 
silencing was achieved without measurable toxicity of either the individual neurons or the 
animal as a whole. However, the dose of IVM required to elicit a consistent silencing 
phenotype (5–10 mg/kg; Figure 4-1B)1 was unexpectedly higher than that routinely used 
to treat mice with parasitic infections (0.2 mg/kg)4 and high enough to raise concern 
about potential side effects. Though IVM can successfully cross the BBB, some fraction 
is presumably being cleared continuously from the brain by the mdr1a P-glycoprotein 
transporter5, resulting in a lower effective concentration in the cerebrospinal fluid. 
Further increasing the dose (20 mg/kg) enters the range of toxicity, visible by paralysis6. 
Toxic effects are likely mediated through off-target agonism, as IVM is known to activate 
or potentiate other ligand-gated ion channels present in the CNS, though it does so with 
much lower affinity7-10. 
Silencing experiments with the GluCl/IVM system were also subject to 
considerable variability. Rotation data from the in vivo study displays a bimodal 
distribution with one group of animals exhibiting a weak but significant phenotype, and 
the other exhibiting a strong behavioral phenotype. The strength of the behavioral 
phenotype was correlated with both the extent of viral infection (i.e., the volume of 
striatum expressing GluCl αβ) and the extent of spike suppression (i.e., individual  
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Figure 4-1.  Proof-of-concept for GluCl/IVM neuronal silencing in vivo.  A. Experimental design 
schematic of amphetamine-induced rotation test for silencing striatal neurons. Unilateral striatum was 
virally infected with GluCl α and β subunits. Control mice move around the chamber perimeter. Mice 
expressing GluCl and administered IVM display rotational behavior.  B. Dose-response relation for 
amphetamine-induced rotation.  C. Histogram of rotation score shows bimodal distribution. Strength of the 
phenotype correlates with the volume of the virally infected region.  D. Neuron firing rates show full, 
partial and no inhibition. Lowercase letters display sample spike trains before (a) and after (b & c) IVM 
perfusion. Strength of the phenotype correlates with the extent of spike suppression.  E. Confocal images 
show varying subunit expression levels. Extent of spike suppression is correlated with fluorescence 
intensity of α-CFP and β-YFP Y182F subunits. (Figures adapted from Lerchner et al., 2007.)1 
score A 
B C 
D 
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neurons showing either full, partial, or no inhibition), which further correlated with co-
expression levels of α and β subunits (Figure 4-1C, D, E). 
Prior to its implementation as a silencing tool, the GluCl receptor was modified in 
several ways. First, it was rendered insensitive to its native ligand glutamate by a single 
point mutation in the β subunit, Y182F (Figure 4-2A)11. Insensitivity is necessary since 
glutamate is an endogenous neurotransmitter present in cerebrospinal fluid and released 
during synaptic transmission. In addition, the DNA sequence of this invertebrate gene 
was codon-optimized to achieve greater expression levels in mammalian systems (Figure 
4-2B)12, and tagged with fluorescent proteins YFP and CFP for direct visualization of 
protein expression (Figure 4-2C)11. This GluCl opt α-CFP + opt β-YFP Y182F receptor 
is referred to throughout this study as ‘the original tool’.  
 
 
 
Figure 4-2.  Construct modifications generating the original GluCl opt α-CFP + opt β-YFP Y182F 
silencing tool.  A. A tyrosine-to-phenylalanine mutation at position 182 of the β subunit abolishes 
glutamate sensitivity but maintains activation by IVM.  B. Codon optimization of GluCl subunits increased 
expression levels in mammalian cells.  C. Fluorescent labels, CFP and YFP, were inserted into the 
intracellular M3-M4 loop for direct visualization of subunit expression. (Figures adapted from Li et al., 
2002; Slimko et al., 2002; Slimko & Lester, 2003.)11-13 
!"#$%&'$ !"#$()#$
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The current study aimed to optimize the original GluCl/IVM tool by introducing 
rational point mutations intended to (1) increase receptor sensitivity to IVM in order to 
achieve silencing by lower doses and, (2) improve subunit expression at the plasma 
membrane in order to reduce spike suppression variability. Such optimization would 
alleviate the concern of off-target side effects and avoid suboptimal spike inhibition. As 
was the subject of Chapter 3, introduction of an L9’F gain-of-function mutation in the 
second transmembrane domain of the α subunit appears to facilitate β subunit 
incorporation and substantially increase heteromeric GluCl αβ sensitivity to IVM without 
permitting unliganded channel opening. Glutamate insensitivity must be reinstated to this 
high sensitivity mutant receptor for it to function effectively as a silencing tool. It was 
also determined that GluCl α homomers are indeed expressed at the plasma membrane of 
mammalian cells and are responsive to IVM. A mixed presence of heteromeric and 
homomeric receptors could be responsible for the variability in spike suppression. To 
address this possibility in the current study, the secretory pathway of membrane receptor 
trafficking was considered. Rational protein engineering strategies to improve 
heteromeric GluCl αβ surface expression may be combined with the increased sensitivity 
mutation to produce an optimized GluCl/IVM silencing tool. 
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Results 
Mutation of a putative ER retention motif enhances IVM sensitivity 
In the cell, multimeric receptors destined for the plasma membrane are synthesized, 
matured, and assembled at the endoplasmic reticulum (ER)14,15. The amino acid sequence 
contains specific signaling motifs that instruct the cellular machinery to either let the 
protein exit the ER or retain it there. Subunits that have been assembled into complete 
receptors are prepared for ER export at ‘exit sites’ where they are packaged into coat 
protein II (COPII) vesicles that mediate anterograde transport from the ER to the Golgi. 
In the Golgi, receptors are either subject to posttranslational modifications after which 
they are trafficked to the plasma membrane, or they undergo retrograde transport (i.e., 
retrieval) by COPI vesicles back to the ER. This ER retention-retrieval process serves as 
a quality control mechanism to ensure that only properly assembled receptors are 
transported to the cell surface. Proteins that are misfolded, unassembled, or improperly 
assembled are retained in the ER and ultimately targeted for ER-associated 
degradation16,17. 
Consensus signaling motifs exist for both ER export and ER retention. The best-
characterized exit signals include DxE18,19, LxxL/ME20, and I/LxM21. These ER export 
motifs are found on the cytosolic loops of a variety of membrane-associated proteins and 
are recognized by Sec24, the primary cargo-selection protein of the COPII coated 
vesicles for transport from ER to Golgi. Well-described ER retention signals include the 
classical C-terminal motifs, KDEL and KKxx22,23, and the cytosolic arginine-based 
signal, RxR24. The RxR motif has been found in potassium channels24, G-protein coupled 
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receptors25, voltage-dependent Ca2+ channels26, ionotropic glutamate receptors27-29 and 
ionotropic Cys-loop receptors30-32. Proteins containing an RxR motif are retained in the 
ER or maintained by COPI retrieval until the signal is masked as a result of 
heteromultimeric assembly with additional subunits33-35.  
To check for putative ER signaling motifs present in GluCl α and β, the amino 
acid sequence of the large TM3–TM4 intracellular loop of each subunit was examined 
(Figure 4-3). The α subunit has one potential ER export motif, LNLLE, immediately 
following the fluorescent fusion protein insertion (note, XFP tags were originally placed 
in TM3–TM4 loop at restriction sites11). The β subunit has two putative ER export 
motifs, LEM and DAE, as well as two putative ER retention motifs, RSR and RRR. The 
presence of these possible signaling motifs correlates with functional expression observed 
for each of these subunits in mammalian systems. In HEK293 cells, heteromeric GluCl 
αβ channels are activated by glutamate and IVM; α homomers form functional channels 
at the plasma membrane responsive to IVM, while no response is observed for β 
homomers with either glutamate or IVM. It is possible that one or both of the ER 
retention motifs present in the β subunit prevents its trafficking to the plasma membrane 
in the absence of α subunits, fitting with the premise that subunits bearing an arginine-
based ER retention motif require ‘masking’ by assembly with other appropriate subunits 
in order to exit the ER. It also suggests that variability in receptor expression and 
silencing could be due to ER retention of the β subunit. Thus, removal of ER retention 
signals may allow more uniform receptor expression and consistent neuronal silencing. 
To test this hypothesis, the putative ER retention motifs of GluCl β were mutated to 
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alanine residues: GluCl β-YFP R318A, S319A, R320A for a ‘RSR_AAA mutant’ and 
GluCl β-YFP R329A, R330A, R331A for a ‘RRR_AAA mutant’.  
 
 
 
Figure 4-3.  Putative ER signaling motifs in GluCl α  and β  subunits.  Amino acid sequence including 
the intracellular TM3–TM4 loop of GluCl α and GluCl β subunits. The last amino acid of each sequence is 
the C-terminal residue. Transmembrane spanning helices (TM3 and TM4) are defined by blue rectangles. 
Position of the fluorescent protein insertion is noted by ‘XFP’. ER export motifs are shown in green boxes; 
ER retention motifs are shown in orange boxes. The α subunit contains a single putative ER export motif 
(LxxL/ME). The β subunit contains two possible ER export motifs (I/LxM; DxE) and two potential ER 
retention motifs (RxR). 
 
Mutant β subunits were expressed as heteromeric receptors and tested for IVM 
activation using a membrane potential assay to ensure that the RSR_AAA and 
RRR_AAA mutations did not disrupt channel function. The α-YFP + β-YFP RSR_AAA 
and α-YFP + β-YFP RRR_AAA mutant receptors, and the double mutant receptor, α-
YFP + β-YFP RSR_AAA&RRR_AAA, each displayed a concentration-dependent IVM 
response similar to the WT and WT-XFP receptors (Figure 4-4A, Table 4-1). No 
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response was observed for any of the mutated β subunits when transfected in the absence 
of the α subunit, suggesting that removal of these putative retention motifs is not 
sufficient to allow membrane expression of β homomers. Noticeable differences 
including a biphasic dependency of the (β)RSR_AAA mutant and increased raw RFU 
signal (Figure 4-4B) for both the (β)RSR_AAA and (β)RRR_AAA mutants conveyed 
these mutations were having an effect. Removal of an ER retention motif could either be 
increasing the total number of receptors expressed at the surface, or shifting the receptor 
subunit stoichiometry, or both. 
 
 
 
Figure 4-4.  Ivermectin concentration-response curves for putative ER retention mutants. IVM 
activation was assayed using the FlexStation.  A. Normalized IVM concentration-response curves for the 
heteromeric (β)RSR_AAA, (β)RRR_AAA, and (β)RSR_AAA&RRR_AAA mutant receptors are similar to 
WT and WT-XFP. IVM activation parameters are shown in Table 4-1.  B. The (β)RSR_AAA and 
(β)RRR_AAA mutants show increased raw RFU signals. 
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If removal of the putative retention motifs increases the number of receptors 
trafficked to the plasma membrane, it should result in greater whole-cell currents. 
Avoiding the issues with IVM electrophysiology as discussed in the previous chapter, 
glutamate-induced currents of the heteromeric (β)RSR_AAA and (β)RRR_AAA mutant 
receptors were recorded in whole-cell patch-clamp mode using the Dynaflow 
microperfusion chip. Pooled concentration-response relations of these mutants were again 
similar to WT and WT-XFP, but there was no statistically significant increase in maximal 
current for the number of cells recorded (Figure 4-5A, B). Multiple sensitivities were 
observed as before (Figure 4-5C; Chapter 3, Figure 3-3) with comparable EC50 values and 
a greater number of cells showing a ‘low sensitivity’ response to glutamate.  
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Figure 4-5.  Glutamate concentration-response curves for putative ER retention mutants. Glutamate 
activation was assayed by whole-cell electrophysiology.  A. Normalized glutamate concentration-response 
curves for heteromeric (β)RSR_AAA and (β)RRR_AAA mutant receptors are similar to WT and WT-XFP.  
B.  Maximal glutamate-induced currents of the mutant receptors are not significantly different from WT 
and WT-XFP.  C. Concentration response curves of individual cells could be separated into three 
categories: high sensitivity (red line), low sensitivity (blue line), and mixed (green line). Glutamate 
activation parameters for putative ER retention mutants are presented in the corresponding tables. Curves 
for cell-to-cell variability of WT and WT-XFP are shown in Chapter 3, Figure 3-3. The EC50 and Hill 
coefficient values represent the mean ± SEM for the number of cells (n) recorded. The * indicates 
concentration-response normalization to a less-than-saturating maximum concentration.   
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In the previous chapter, introduction of an (α)L9’F mutation yielded a biphasic 
concentration-dependent relationship with increased sensitivity to IVM (Chapter 3, 
Figure 3-6). Addition of the (α)L9’F mutation with the putative ER retention mutations 
produced pronounced two-component relationships for both the (α)L9’F + (β)RSR_AAA 
and the (α)L9’F + (β)RSR_AAA&RRR_AAA mutant receptors (Figure 4-6A). In 
particular, the (α)L9’F + (β)RSR_AAA mutant receptor shows a significant increase in 
activation with low (10 nM) concentrations of IVM (Figure 4-6B).  
 
 
 
Figure 4-6.  IVM concentration-response curves for putative ER retention mutants plus the (α)L9’F 
mutation. IVM activation was assayed using the FlexStation.  A. Normalized IVM concentration-response 
curves for (α)L9’F + (β)RSR_AAA and (α)L9’F + (β)RSR_AAA&RRR_AAA show a pronounced 
biphasic relationship. IVM activation parameters are shown in Table 4-1.  B. The (α)L9’F + (β)RSR_AAA 
mutant receptor is significantly more sensitive to 10 nM IVM than WT. 
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Glutamate insensitive mutations eliminate increased sensitivity to IVM 
The significant increase in IVM sensitivity was encouraging toward the goal of 
GluCl optimization. The (α)L9’F and β subunit ER retention mutations tested up to this 
point, however, had been examined using glutamate-sensitive receptors. True 
optimization of the silencing tool requires glutamate insensitivity, accomplished by the 
binding site mutation, Y182F, in the β subunit. Astonishingly, reintroduction of the 
(β)Y182F mutation into the (α)L9’F + (β)RSR_AAA receptor abolished the high IVM 
sensitivity component of the biphasic concentration-response curve (Figure 4-7A). The 
same loss of high IVM sensitivity was observed when the glutamate insensitive 
(β)Y182F mutation was restored to the individual (α)L9’F and  (β)RSR_AAA mutant 
receptors (Figure 4-7B, C).  
 
 
 
Figure 4-7.  Reintroduction of a glutamate insensitive mutation affects IVM sensitivity of proposed 
optimized receptor. IVM activation was assayed using the FlexStation. Normalized IVM concentration-
response curves show presence of a (β)Y182F mutation eliminates the high sensitivity component of the 
biphasic relationship for the combined (α)L9’F + (β)RSR_AAA mutant receptor (A) as well as the 
individual (α)L9’F and (β)RSR_AAA mutant receptors (B&C). IVM activation parameters are shown in 
Table 4-1. 
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In spite of these effects, the (β)Y182F mutation alone was confirmed to behave as 
expected, rendering heteromeric GluCl αβ receptors insensitive to glutamate without 
affecting IVM sensitivity (Figure 4-8).  
 
 
 
Figure 4-8.  Confirmation of the (β)Y182F glutamate insensitive mutation. Glutamate (raw RFU) and 
IVM (normalized RFU) activation were assayed using the FlexStation. The (β)Y182F mutation renders 
heteromeric GluCl receptors insensitive to glutamate (A) while maintaining sensitivity to IVM (B). IVM 
activation parameters are shown in Table 4-1. 
 
The incompatibility of the (β)Y182F mutation prompted the consideration of 
alternative mutations to achieve glutamate insensitivity. A recently available crystal 
structure of GluCl provides the precise molecular interactions of glutamate within the 
receptor binding site (Figure 4-9A)36. Structural coordinates reveal a cation-pi interaction 
between the electron-rich aromatic ring of a tyrosine residue (Y200 of GluClcryst) and the 
positively charged amino group of glutamate. This tyrosine residue corresponds to Y261 
of the nascent α subunit which aligns with Y232 of the nascent β subunit (note, nascent 
numbering includes signal peptide residues). Since the resolved structure is comprised of 
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only α subunits, it is not known which subunit, α or β, provides the principle and 
complimentary faces of the binding site in the heteromeric receptor. For that reason, the 
potential cation-pi-forming tyrosine residue of each subunit was mutated to alanine, 
(α)Y261A and (β)Y232A, and tested individually for glutamate and IVM activation. 
The (β)Y232A mutant was successful in abolishing glutamate sensitivity while 
perfectly maintaining IVM sensitivity (Figure 4-9B, C). The (α)Y261A mutant was also 
insensitive to glutamate (Figure 4-9E). However, the IVM concentration-response curve 
for this mutant was right-shifted with a steep Hill coefficient, much like that observed for 
GluCl α-YFP homomers (Figure 4-9F; see Chapter 3, Figure 3-7). This suggests that the 
(α)Y261A mutation gives rise to a predominating population of α homomer receptors, 
which are inherently unresponsive to glutamate binding events. Though not conclusive, 
these results suggest that β serves as the principle subunit of heteromeric GluCl αβ 
receptors. To determine if (β)Y232A could function as an alternative glutamate 
insensitive mutation toward an optimized silencing tool, it was combined with the 
(α)L9’F mutation. Unfortunately, the high sensitivity component of the biphasic (α)L9’F 
response was still not maintained (Figure 4-9D).   
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Figure 4-9.  An alternative glutamate insensitive mutation still does not maintain high IVM 
sensitivity.  A. Glutamate binding interactions with GluClcryst α homomer. (Figure adapted from Hibbs & 
Gouaux, 2011.)36 The Y200 residue forms a cation-pi interaction with the amino group of glutamate.  B–F. 
Glutamate (raw RFU) and IVM (normalized RFU) activation were assayed using the FlexStation.  B&C. 
The (β)Y232A mutation renders heteromeric receptors insensitive to glutamate while maintaining 
sensitivity to IVM.  D. The (β)Y232A mutation still eliminates the high sensitivity component of the 
(α)L9’F biphasic response.  E&F. The (α)Y261A mutant receptor is also insensitive to glutamate, but the 
right-shifted IVM concentration-response curve suggests predominant expression of α homomers which 
are already insensitive to glutamate. IVM activation parameters are shown in Table 4-1. 
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XFP tag oligomerization affects IVM sensitivity 
Reappearance of the steep, right-shifted IVM concentration-response curve characteristic 
of the GluCl α-YFP homomers warranted a closer look at the effects of fluorescent 
protein insertion. A four-way comparison of heteromeric WT-XFP receptors with YFP 
and CFP tags on either or both subunits shows a right shift from the nontagged WT 
receptor (Figure 4-10A). Cross-comparison of XFP-tagged and nontagged subunits 
revealed right-shifted curves only when the fluorescent protein was present in the α 
subunit (Figure 4-10B). It appears the XFP insertion in the α subunit affects IVM 
sensitivity of both α homomeric and αβ heteromeric receptors.  
 
 
 
Figure 4-10.  The α  subunit fluorescent protein (XFP) insertion affects IVM sensitivity.  IVM 
activation was assayed using the FlexStation.  A. Heteromers with YFP and CFP tags on either or both 
subunits all show a slight right shift from the nontagged WT receptor.  B. Heteromers with a YFP or CFP 
tag on one subunit shows right-shifted curves only when the fluorescent protein is on the α subunit. 
Ivermectin activation parameters are presented in the corresponding table. 
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!'()*%&%"'+)*# 365.20 ± 96.76 0.99 ± 0.16 12 
!'()*%&%"'()*# 302.08 ± 54.34 1.44 ± 0.27 12 
!'+)*%&%"'()*# 249.59 ± 57.09 0.94 ± 0.15 6 
!'+)*%&%"'+)*# 490.25 ± 39.35 1.89 ± 0.24 6 
!!"#$%&%"'+)*# 110.26 ± 13.09 0.96 ± 0.08 6 
!!"#$%&%"'()*# 123.85 ± 17.74 1.16 ± 0.15 6 
!'()*%&%"!"#$# 471.85 ± 35.39 1.58 ± 0.14 6 
!'+)*%&%"!"#$# 255.72 ± 11.82 2.16 ± 0.17 6 
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Fluorescent proteins have a tendency to dimerize at high concentrations. A crystal 
structure of GFP shows a hydrophobic dimer interface comprised of amino acid residues 
Ala206, Leu221, and Phe223 (Figure 4-11A)37. A strictly monomeric form of XFP can be 
obtained by mutating Ala206 to a Lys residue which introduces a long, positively charged 
side chain that disrupts the hydrophobic interface38. Fluorescent protein dimerization is 
likely to occur when restricted to two-dimensional space as when fused to membrane 
proteins39. To determine if XFP dimerization was having an effect on channel function or 
possibly even stoichiometry of GluCl, an A206K mutation was incorporated into the 
engineered constructs. The IVM concentration-response curve of the wild-type 
monomeric YFP-tagged (mYFP) receptor was no longer right-shifted compared to the 
WT receptor, and even revealed a distinctive second component (Figure 4-11B). 
Incorporation of mYFP into the (α)L9’F receptor produced a more pronounced biphasic 
relationship than any previously observed. The same extreme biphasic behavior resulted 
when the L9’F mutation was present in the β subunit or present both α and β subunits 
(Figure 4-11C). Addition of (β)Y182F to the (α)L9’F mutation with mYFP tags now 
maintained a high sensitivity component, however the proportion was still reduced 
(Figure 4-11D).  
Due the significant improvement of mYFP, this A206K mutation was combined 
iteratively with the L9’F mutations, (α)L9’F and/or (β)L9’F, the glutamate insensitive 
mutations, (β)Y182F or (β)Y232A, and the ER-retention mutation, (β)RSR_AAA, to 
screen for the greatest increase in IVM sensitivity (Figure 4-12A). This process revealed 
high sensitivity IVM activation for the initially favored receptor (α-YFP L9’F + β-YFP 
RSR_AAA) now including a glutamate insensitive mutation and monomeric fluorescent  
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Figure 4-11.  Monomeric YFP mutation (A206K) increases high IVM sensitivity component.  A. 
Crystal structure of GFP dimer (1GFL.pdb) indicates a hydrophobic interface composed of residues 
Ala206, Leu221, and Phe223.  B. Receptors with mYFP tags on both α and β subunits are no longer right-
shifted from the nontagged WT receptor.  C. The incorporation of mYFP enhances the high IVM sensitivity 
component of the (α)L9’F biphasic curve. An L9’F mutation in the β subunit or in both α and β subunits 
gives similar results.  D. The mYFP mutation maintains a high IVM sensitivity component upon addition of 
the (β)Y182F mutation to (α)L9’F. IVM activation was assayed using the FlexStation. IVM activation 
parameters are shown in Table 4-1. 
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Figure 4-12.  Identification of an optimally engineered receptor.  IVM activation was assayed using the 
FlexStation.  A. Normalized IVM concentration-response curves of mutant receptor combinations including 
mYFP tags (all panels) with the (α)L9’F and/or (β)L9’F mutations (all panels), the glutamate insensitive 
mutations (β)Y182F (top panels) and (β)Y232A (bottom panels), and the ER-retention mutation 
(β)RSR_AAA (right panels).  B. GluCl α-mYFP L9’F + β-mYFP Y182F RSR_AAA has the greatest 
increase in IVM sensitivity compared to the original silencing tool. IVM activation parameters are shown 
in Table 4-1. 
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Table 4-1.  Ivermectin activation parameters for various GluCl mutant receptors. Parameters 
correspond to concentration-response curves in Figures 4-4A, 4-6A, 4-7A,B,C, 4-8B, 4-9C,D,F, 4-
11B,C,D, 4-12A,B. The EC50 and Hill coefficient values represent the mean ± SEM for the number of 
measurements (n) obtained. 
 
protein tags. Thus, the mYFP mutation restored the high IVM sensitivity component 
previously lost upon addition of (β)Y182F. The optimized GluCl α-mYFP L9’F + β-
mYFP Y182F RSR_AAA receptor is more sensitive to IVM than the original receptor 
silencing tool by ~2 orders of magnitude (Figure 4-12B, Table 4-1). 
GluCl channel 1
st  
comp EC50 (nM) Hill EC50 (nM) Hill n 
!!"#$%&%"!"#$ 107.14 ± 10.94 1.04 ± 0.09 12 
!'()*%&%"'()* 302.08 ± 54.34 1.44 ± 0.27 12 
!'()*%&%"'()*%+,+-... 0.35 8.55 ± 3.16 2.5 ± 1.67 163.15 ± 38.31 2.04 ± 0.84 6 
!'()*%&%"'()*%+++-... 111.88 ± 9.98 1.44 ± 0.16 6 
!'()*%&%"'()*%+,+-.../+++-...% 233.06 ± 17.71 1.44 ± 0.13 6 
!'()*%012)%&%"'()* 0.61 7.27 ± 2.85 1.14 ± 0.24 185.35 ± 50.16 1.99 ± 0.82 6 
!'()*%012)%&%"'()*%+,+-... 0.53 3.91 ± 1.69 1.64 ± 0.69 95.28 ± 30.91 2.24 ± 1.27 12 
!'()*%012)%&%"'()*%+++-... 83.31 ± 21.70 0.94 ± 0.17 6 
!'()*%012)%&%"'()*%+,+-.../+++-...% 0.39 2.52 ± 0.83 1.81 ± 0.83 243.71 ± 44.61 2.50 ± 0.98 6 
!'()*%&%"'()*%(345) 380.41 ± 105.68 1.14 ± 0.24 6 
!'()*%012)%&%"'()*%(345) 159.81 ± 20.71 1.07 ± 0.12 6 
!'()*%&%"'()*%(345)%+,+-... 365.49 ± 48.35 1.35 ± 0.17 6 
!'()*%012)%&%"'()*%(345)%+,+-... 45.08 ± 5.37 1.21 ± 0.14 6 
!'()*%&%"'()*%(565. 377.56 ± 44.80 1.04 ± 0.08 6 
!'()*%012)%&%"'()*%(565. 304.01 ± 31.67 1.03 ± 0.10 6 
!'()*%(573.%&%"'()* 682.81 ± 34.37 3.04 ± 0.38 6 
!'8()*%&%"'8()* 0.29 3.58 ± 3.66 1.16 ± 0.80 170.46 ± 32.61 2.16 ± 0.79 6 
!'8()*%012)%&%"'8()* 0.49 1.35 ± 0.47 1.36 ± 0.85 185.58 ± 62.75 2.24 ± 1.65 6 
!'8()*%&%"'8()*%012) 0.48 0.68 ± 0.15 2.5 ± 1.25 418.17 ± 165.12 1.75 ± 1.00 6 
!'8()*%012)%&%"'8()*%012) 0.54 0.90 ± 0.24 2.13 ± 1.15 429.33 ± 156.96 2.5 ± 2.00 6 
!'8()*%&%"'8()*%(345) 549.07 ± 50.34 2.11 ± 0.35 6 
!'8()*%012)%&%"'8()*%(345) 0.23 1.59 ± 0.85 1.36 ± 0.85 408.08 ± 49.78 2.5 ± 0.65 6 
!'8()*%&%"'8()*%012)%(345) 134.27 ± 19.92 0.97 ± 0.11 6 
!'8()*%012)%&%"'8()*%012)%(345) 78.38 ± 14.54 1.01 ± 0.15 6 
!'8()*%&%"'8()*%(345)%+,+-... 0.50 9.73 ± 3.98 2.50 ± 2.04 218.57 ± 91.48 2.5 ± 2.47 6 
!'8()*%012)%&%"'8()*%(345)%+,+-... 0.63 3.35 ± 1.36 1.04 ± 0.27 196.26 ± 49.81 2.5 ± 1.64 6 
!'8()*%&%"'8()*%012)%(345)%+,+-... 0.33 4.70 ± 2.98 1.00 ± 0.39 265.91 ± 32.59 2.5 ± 0.61 6 
!'8()*%012)%&%"'8()*%012)%(345)%+,+-... 0.29 9.92 ± 20.71 1.00 ± 1.12 340.09 ± 103.09 2.5 ± 1.41 6 
!'8()*%&%"'8()*%(565. 174.49 ± 38.29 0.83 ± 0.10 6 
!'8()*%012)%&%"'8()*%(565. 0.31 2.61 ± 1.51 1.07 ± 0.48 343.17 ± 52.89 2.5 ± 0.75 6 
!'8()*%&%"'8()*%012)%(565. 311.27 ± 85.60 1.18 ± 0.29 6 
!'8()*%012)%&%"'8()*%012)%(565. 209.70 ± 69.82 1.22 ± 0.38 6 
!'8()*%&%"'8()*%(565.%+,+-... 0.27 1.81 ± 4.53 1.08 ± 1.88 141.98 ± 69.99 1.73 ± 1.27 6 
!'8()*%012)%&%"'8()*%(565.%+,+-... 0.36 21.58 ± 53.57 1.00 ± 0.89 277.64 ± 85.65 2.30 ± 1.31 6 
!'8()*%&%"'8()*%012)%(565.%+,+-... 0.20 3.72 ± 2.11 2.04 ± 1.76 371.81 ± 60.99 1.99 ± 0.54 6 
!'8()*%012)%&%"'8()*%012)%(565.%+,+-... 0.22 3.35 ± 3.06 2.5 ± 4.08 333.88 ± 96.74 2.50 ± 1.34 6 
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Biphasic response is not due to potentiation 
Every instance of increased IVM sensitivity transpired as part of a biphasic response. The 
persistent low sensitivity component and the deleterious effect of including a glutamate 
insensitive mutation on the high sensitivity component were perplexing. With regard to 
the latter issue, it is conceivable that low (nM) glutamate present in the extracellular fluid 
could contribute to the high sensitivity component of the IVM response, since the 
(α)L9’F mutation has increased sensitivity for glutamate in addition to IVM (Chapter 3, 
Figure 3-6). Furthermore, examples of IVM potentiation of the glutamate response, as 
well as, glutamate potentiation of the IVM response have both been reported for GluCl40-
42. If the high sensitivity component of the (α)L9’F biphasic response is due to 
potentiation by low levels of extracellular glutamate, then a glutamate insensitive 
mutation would withdraw the effect.  
To test this possibility, a complex FlexStation assay was conducted. A large 
concentration range of glutamate (from 1 nM to 5 mM) was sampled in the presence of 
10 nM IVM. This concentration of IVM was chosen to represent high sensitivity 
activation, and an additional ‘10 nM IVM only’ dose was included for response 
normalization. This approach probed the possibility of potentiation in both directions, 
identifying (1) whether low concentrations of glutamate potentiate the 10 nM IVM 
response, and (2) if the presence of 10 nM IVM potentiates the glutamate response, both 
at nonactivating and activating concentrations of glutamate. 
Using the mYFP-tagged constructs, the WT, (α)L9’F, (β)Y182F, and the 
combined (α)L9’F + (β)Y182F receptors were assayed. The mean ‘10 nM IVM only’ 
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response was as expected; the (α)L9’F mutation increases IVM sensitivity and addition 
of the (β)Y182F mutation abolishes this effect (Figure 4-13A). For each receptor, low 
glutamate (1 nM to 20 µM) does not potentiate the 10 nM IVM response, as 
normalization results in a value of 1 (Figure 4-13B). For the (α)L9’F receptor in 
particular, higher concentrations of glutamate do not increase the magnitude more than 
that already induced by 10 nM IVM, confirming that extracellular glutamate levels do not 
influence the high sensitivity component of the biphasic response. Furthermore, a plot of 
the raw concentration-response relationship of glutamate in the presence of 10 nM IVM 
is essentially the same as that of glutamate alone (Figure 4-13C). A ratio of the responses 
at 1 mM glutamate reveals, if anything, that the presence of IVM might slightly recover 
some glutamate sensitivity of the (β)Y182F mutant receptor, but it does not potentiate the 
glutamate response of the (α)L9’F mutant receptor (Figure 4-13D).   
 
Biphasic response is due to stoichiometry 
A second possible explanation for the biphasic response, discussed in Chapter 3, is a shift 
in receptor stoichiometry, i.e., a shift in the ratio of α:β subunits in the assembled 
pentamer. The presence of multiple stoichiometric populations with differing agonist 
sensitivities can result in a multicomponent concentration-response curve. In FlexStation 
assays, the expression of GluCl α homomers consistently produces a monophasic curve, 
while co-expression of α with the β subunit has yielded biphasic concentration-response 
curves for several receptors, most prominently in the case of individual (α)L9’F and 
(β)RSR_AAA mutant receptors. For a simple test to determine if stoichiometry could be 
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Figure 4-13.  Potentiation does not explain the biphasic response of (α)L9’F mutant receptors.  IVM 
activation was assayed using the FlexStation.  A. Mean response of WT, (α)L9’F, (β)Y182F, and (α)L9’F 
+ (β)Y182F receptors to a ‘10 nM IVM only’ application (for normalization).  B. Signals of twenty-one 
increasing concentrations of glutamate in the presence of 10 nM IVM normalized by the ‘10 nM IVM only’ 
response. Low concentrations of glutamate (1 nM to 20 µM) do not potentiate the 10 nM IVM response.  C. 
Raw RFU signal for activating concentrations of glutamate in the presence of 10 nM IVM (last 7 doses) is 
comparable to that of glutamate alone.  D.  Response ratio for 1 mM glutamate shows 10 nM IVM does not 
potentiate the glutamate response of (α)L9’F mutant receptors. 
 
responsible for the biphasic response of these two mutant receptors (tagged with mYFP), 
different ratios of α and β DNA (1:1, 4:1, and 1:4) were transfected into HEK293 cells 
and assayed on the FlexStation. As previously observed for both cases, a 1:1 ratio 
0
50
100
150
R
F U
L9'F +
Y182F
Y182FL9'FWT
!"#$%&'$%
(#)*%
A 
0 5 10 15 20
0
2
4
6
8
10
12
m
e a
n  
r a
t i o
Glutamate Dose #
0 5 10 15 20
0
2
4
6
8
10
12
m
e a
n  
r a
t i o
Glutamate Dose #
0 5 10 15 20
0
2
4
6
8
10
12
m
e a
n  
r a
t i o
Glutamate Dose #
0 5 10 15 20
0
2
4
6
8
10
12
m
e a
n  
r a
t i o
Glutamate Dose #
!"# $%&'# ()*+'! $%&',()*+'!
B -./,)012#342#####)012#342#
0
2
4
6
8
10
12
 L9'F +
Y182F
Y182FL9'F
r a
t i o
WT
!"#$%&'(!)*#$+,#$
$$$$$$$$$!"#$%&'$
10-4 10-3 10-2 10-1 100 101 102 103 104
0
100
200
300
400
R
F U
[Glutamate] (?M)
with 10nM IVM
0.01 0.1 1 10
0
100
200
300
400
R
F U
[Glutamate] (mM)
-$
C D 
	   107	  
produced a two-component concentration-dependent relationship. Biasing for β (1:4), in 
general, showed no further increase in IVM sensitivity, while biasing for α (4:1) indeed 
showed a decrease in IVM sensitivity (Figure 4-14). Therefore, incorporation of the β 
subunit confers increased sensitivity to IVM, but requires unbiased co-expression with 
the α subunit for the maximum effect. This confirms multiple receptor populations are 
contributing to the biphasic concentration-response curve but the stoichiometric identities 
remain to be determined. 
 
 
 
 
 
Figure 4-14.  Multiple receptor stoichiometries explain the biphasic response.  IVM activation was 
assayed using the FlexStation.  A. Different ratios of α and β DNA (1:1, 4:1, and 1:4) were transfected into 
HEK293 cells. The 1:1 ratio (red) produced the expected two-component concentration-dependent 
relationship for (α)L9’F (panel A.) and (β)RSR_AAA (panel B.) mutant receptors. Biasing for β (1:4, 
aqua) does not further enhance IVM sensitivity. Biasing for α (4:1, orange) decreases in IVM sensitivity. 
Ivermectin activation parameters are presented in the corresponding table. 
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comp EC50  (µM) Hill EC50  (µM) Hill n 
!!"#$%&'()$&*&"!"#$%&&&&&+,+&# 0.64 1.37 ± 1.16 1.00 ± 0.40 65.16 ± 70.35 1.17 ± 0.86 6 
!!"#$%&'()$&*&"!"#$%&&&&&-,+&# 0.26 2.38 ± 2.64 1.00 ± 0.61 147.24 ± 27.16 1.66 ± 0.42 6 
!!"#$%&'()$&*&"!"#$%&&&&&+,-&# 0.58 0.92 ± 0.29 1.39 ± 0.56 178.36 ± 61.16 2.17 ± 1.51 6 
!!"#$%&*&"!"#$%&./.0111&&&&&+,+&# 0.47 9.56 ± 3.60 2.50 ± 1.90 220.21 ± 76.06 2.50 ± 2.03 6 
!!"#$%&*&"!"#$%&./.0111&&&&&-,+&# 184.22 ± 16.99 1.42 ± 0.15 6 
!!"#$%&*&"!"#$%&./.0111&&&&&+,-&# 0.15 5.58 ± 20.08 1.00 ± 1.64 188.88 ± 42.35 1.95 ± 0.78 6 
	   108	  
Retention mutations are not sufficient for β  homomer surface expression 
The fluorescent protein insertions allow direct visualization and localization of GluCl 
receptors expressed in a cell. TIRF images of HEK293 cells show GluCl α homomers 
and αβ heteromers are expressed at the plasma membrane; GluCl β homomers are not 
(Figure 4-15). Specifically, the α-mYFP subunit shows plasma membrane fluorescence 
when transfected alone or cotransfected with β(WT). Plasma membrane fluorescence is 
also observed when the β-mYFP subunit is cotransfected with α(WT). Transfection of 
the β-mYFP subunit alone, however, displays exclusive ER retention, as indicated by a 
reticulated pattern of fluorescence and a lack of hair-like filopodia at the periphery. GluCl 
β-mYFP subunits bearing either the individual RSR_AAA or RRR_AAA mutations, or 
the double RSR_AAA&RSR_AAA mutation, display a similar fluorescence pattern as 
seen for the β-mYFP homomer (Figure 4-16). Thus, mutation of the putative ER 
retention motifs in the β subunit is not sufficient to allow plasma membrane expression of 
β homomers. 
Western blot analysis was performed to determine if the putative ER retention 
mutations were increasing heteromeric incorporation of the β subunit at the plasma 
membrane. Receptors composed of untagged α and the different mYFP-tagged β 
subunits were expressed in HEK293 cells and probed for only β subunit expression using 
a GFP antibody. Whole-cell lysate analyses suggest slightly increased protein expression 
levels for mutated β subunits, despite a similar trend in nonspecific staining (Figure 4-
17A). Biotinylation of surface exposed receptors indicates no difference in the number of 
β subunits assembled into pentamers at the plasma membrane (Figure 4-17B). It should 
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Figure 4-15.  GluCl subunit expression in HEK293 cells.  A. TIRF images show GluCl αβ heteromers 
and α homomers are expressed at the plasma membrane. The α-mYFP subunit shows plasma membrane 
fluorescence when transfected alone or cotransfected with β(WT). Plasma membrane fluorescence is also 
observed when the β-mYFP subunit is cotransfected with α(WT).  B. GluCl β homomers are not expressed 
at the plasma membrane. Transfected alone, the β-mYFP subunit displays a reticulated pattern of 
fluorescence indicative of ER retention and a lack of hair-like filopodia at the periphery.  
 
 
 
 
 
Figure 4-16.  GluCl β  homomers containing putative ER retention motif mutations still do not exit 
the ER.  TIRF images of HEK293 cells transfected with β-mYFP subunits bearing either the individual 
putative ER retention motif mutations (RSR_AAA or RRR_AAA) or the double mutation 
(RSR_AAA&RRR_AAA) show a fluorescence pattern similar to β-mYFP homomers.  
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be noted that protein bands in these Western blot experiments were visualized by 
enhanced chemiluminescence with horseradish peroxidase and exposed on radiography 
film. This method has a limited linear dynamic range so quantification in these instances 
may be unreliable.  
 
 
 
 
Figure 4-17.  Western blot analysis of GluCl β-mYFP subunit expression in HEK293 cells. 
Quantification of mutated β-mYFP subunits obtained (A.) from whole-cell lysate preparations for total 
protein expression and (B.) using a surface biotinylation assay for plasma membrane expression. Protein 
bands of transferred gels were detected using rabbit anti-GFP primary antibody and goat anti-rabbit HRP 
secondary antibody. Cells were transfected with the following subunits:  
1.  α(WT) + β-mYFP 
2.  α(WT) + β-mYFP RSR_AAA 
3.  α(WT) + β-mYFP RRR_AAA 
4.  α(WT) + β-mYFP RSR_AAA&RRR_AAA 
5.  nontransfected control 
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RSR mutation increases β  subunit expression 
HEK293 cells are a convenient system for studying receptor function. However, it is 
possible that receptor trafficking events in HEK293 cells could be different from that of 
neurons, especially with respect to stoichiometric preference. Primary neuronal cultures 
provide a more appropriate environment for in vitro experiments. To detect differences in 
the neuronal expression of GluCl, fluorescently tagged subunits were transfected into 
embryonic rat hippocampal neurons. Preliminary confocal images in Figure 4-18 
illustrate a deficient expression pattern for GluCl β homomers with minimal extension 
into the processes and comparatively few fluorescent neurons per imaging dish. GluCl α 
homomers, and various αβ heteromers, on the other hand, exhibit extensive fluorescent 
projections with no discernable differences. Fluorescence intensity of transfected neurons 
varies greatly from cell-to-cell within an imaging dish, so direct measure of integrated 
density is often uninformative. Since neurons have ER compartments throughout much of 
the length of their processes, it can be difficult to distinguish between receptors retained 
in the ER and those expressed at the plasma membrane without the use of colocalization 
markers. 
To target only receptors expressed at the plasma membrane, a live cell 
immunofluorescent surface staining protocol was devised. A V5 epitope tag was added to 
the C-terminus of both α and β subunits (Figure 4-19A). To ensure that addition of the 
V5-tags did not disrupt protein folding and pentameric assembly, tagged subunits were 
assayed for channel function in HEK293 cells using the FlexStation. The V5-tagged 
constructs formed functional channels similar to WT-mYFP when the V5 tag was present 
on either α or β subunits. Receptors with V5 tags on both α and β subunits did not show  
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Figure 4-18.  Confocal images of transfected rat hippocampal neurons with fluorescent GluCl 
receptors.  Image brightness and contrast was adjusted to compare neuronal processes and soma 
separately. Extensive fluorescent projections are apparent for GluCl α homomers and various αβ 
heteromers. A deficient expression pattern is observed for GluCl β homomers with minimal extension into 
the processes. 
 
 
a biphasic response, suggesting a slight interference of heteromeric receptor assembly or 
function with five tagged subunits (Figure 4-19B). Even though inclusion of these penta-
tagged receptors would not be critical for data interpretation in the following experiment, 
they were sampled for the sake of completeness. 
 
!!"#$%!&'()**
+,-,-./"
#!"#$%#&'()*
+,-,-./"
#!"#$*0**
!&'()*'123("
#!"#$*0**
!&'()*'123(*4546777"
#!"#$*0**
!&'()*4546777"
38*µ-*
	   113	  
 
 
 
Figure 4-19.  Addition of a C-terminal V5 epitope tag does not disrupt pentameric assembly and 
function.  A. The V5 epitope tag (also including a 24-residue linker and a 6-His tag; see Materials and 
Methods) was added to the C-terminus of both α and β subunits.  B. Fluorescently labeled heteromeric 
receptors with V5 tags present on either α or β (red and green) show a normalized IVM concentration-
response curve similar to WT-mYFP. Receptors with V5 tags on both α and β subunits (blue) did not show 
the same two-component response, but had comparable functionality. IVM activation was assayed using 
the FlexStation. 
 
Rat hippocampal cultures were transfected with α-mYFP and β-mYFP bearing a 
V5 tag on either or both subunits for three heteromeric receptor conditions: GluCl α-
mYFPV5 + β-mYFP, GluCl α-mYFP + β-mYFPV5, and GluCl α-mYFPV5 + β-
mYFPV5. Surface exposed receptors were labeled with anti-V5 primary and fluorescent 
Alexa 555-conjugated secondary antibodies for confocal imaging. Yellow fluorescence 
contributed by both subunits (mYFP) represented total protein expression, including 
receptors remaining in subcellular compartments and expressed at the plasma membrane. 
Red fluorescence from live cell immunostaining (Alexa 555) labeled only subunits 
...(C-TERM)ASKGNSADIQHSGGRSSLEGPRFEGKPIPNPLLGLDSTRTGHHHHHH 
!"#$%&# '()#$%&#A 
0.1 1 10 100 1000 10000
0.0
0.2
0.4
0.6
0.8
1.0
R
F U
 n
o r
m
a l
i z
e d
[Ivermectin] (nM)
B 
!!"#$%&'&"!"#$%#
!!"#$%!"&'&"!"#$%#
!!"#$%&'&"!"#$%!"#
!!"#$%!"&'&"!"#$%!"#
	   114	  
expressed at the cell surface. Red and yellow fluorescent images were acquired as z-
stacks and examined for colocalization on a pixel-by-pixel basis. The intensity correlation 
between a pair of pixels was scored by calculating the normalized mean deviation 
product (nMDP, see Methods) and visualized on a color scale. Values range from −1 to 1, 
with values less than zero representing exclusion in cold colors, and values greater than 
zero signifying colocalization in hot colors (Figure 4-20A). Thus, for a given pixel, a 
perfect nMDP value of 1 indicates that maximum intensity yellow fluorescence is 
colocalized with maximum intensity red fluorescence. An nMDP value of −1 results 
when a pair of pixels contains maximum fluorescence intensity of one color and zero 
fluorescence intensity for the other color. An nMDP value of zero denotes black 
background. All pixels including and deviating from these extremes can be represented 
by a histogram (Figure 4-20B). Colocalization is evidenced by all positive nMDP values 
(0< x ≤1) and occurs only for receptors expressed at the surface. Hence, greater nMDP 
values indicate a greater amount of GluCl expression at the plasma membrane. 
The average of all positive nMDP values represents total surface expression levels 
of receptor (note, surface expression levels are not well represented by the sum of all 
positive nMDP values as the sum is distorted by the size and number of cells imaged). 
Heteromeric receptors show the same level of surface expression regardless of whether 
the V5 tag was on the α or β subunit (Figure 4-21A). Lower values were observed when 
V5 tags were on both subunits, suggesting either lower expression levels or inefficient 
labeling of all subunits. Transfection of individual V5-tagged subunits corroborated the 
previous HEK293 cell observations that α homomers are expressed at the plasma 
membrane of neurons at levels comparable to αβ heteromers, but that β homomers are 
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not. Heteromeric receptors bearing putative ER retention mutations were assayed in the 
same format (Figure 4-21B). Incorporation of the (β)RRR_AAA or the double 
(β)RSR_AAA&RRR_AAA mutations resulted in lower surface expression levels but in a 
similar manner as WT-mYFP (i.e., less expression when V5 tags are on both α and β 
subunits). Receptors with the (β)RSR_AAA mutation had the same surface expression 
levels as WT-mYFP receptors, but in this case, levels were not reduced when V5 tags 
were on both α and β subunits. 
A comparison of the average number of nMDP = 1 values shows that a greater 
number of maximally correlated pixels occur with V5-tagged α than V5-tagged β when 
WT and the (β)RRR_AAA and (β)RSR_AAA&RRR_AAA mutant receptors are 
expressed as heteromers (Figure 4-21C). The average number of nMDP = 1 values is 
again low when the V5 tag is present on both subunits for these receptors. The 
(β)RSR_AAA heteromeric receptors, on the other hand, show the opposite result. 
Maximal colocalization occurs more often for V5-tagged β than V5-tagged α, and the 
average number of nMDP = 1 values is high when the V5 tag is present on both subunits. 
Altogether, immunofluorescent results suggest that mutation of the putative β subunit 
RSR ER retention motif does not increase the total number of receptors trafficked to the 
plasma membrane, but it may increase the number of β subunits incorporated into the 
pentamer, shifting the stoichiometric ratio of assembled receptors. 
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Figure 4-20.  Colocalization of immunofluorescent surface staining and intrinsic mYFP fluorescence 
of GluCl.  A. Confocal image of GluCl α-mYFPV5 + β-mYFP viewed with the colocalization color scale. 
(All subunits are fluorescently labeled; only the α subunits expressed at the surface are immunostained.) 
An nMDP correlation value is calculated for each pixel based on fluorescence intensity. Values range from 
−1 to 1. Colocalization is shown in hot colors (nMDP > 0); Exclusion is shown in cold colors (nMDP < 0).  
B. Sample histogram of nMDP values. The y-axis is zoomed in for each panel. All positive nMDP values 
(representing colocalization) indicate expression levels at the surface. Colored bars reflect constructs in 
Figure 4-21.  
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Figure 4-21.  The RSR_AAA mutation increases β  subunit surface expression but not total receptor 
surface expression.  Confocal colocalization analysis of surface labeled receptors.  A. Average of all 
positive nMDP values represents total surface expression levels. GluCl α homomers are expressed at the 
plasma membrane, β homomers are not. The same level of heteromer surface expression was obtained 
regardless of whether the V5 tag was on the α or β subunit. Lower expression was observed when V5 tags 
were on both subunits.  B. Receptors bearing putative ER retention motif mutations do not increase total 
receptor surface expression compared to V5-tagged WT (panel A.).  C. Average number of nMDP = 1 
values indicates more maximally correlated pixels occur with V5-tagged α than V5-tagged β when WT, 
RRR_AAA, and RSR_AAA&RRR_AAA receptors are expressed as heteromers. The RSR_AAA mutant 
receptor shows more maximal colocalization with V5-tagged β subunit than V5-tagged α, suggesting a 
shift in stoichiometry.  D. Legend of constructs indicated by color and the number of cells sampled for 
each. 
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Figure 4-22.  The RSR_AAA mutation increases the amount of β  subunit in the ER.  A. Confocal 
images of GluCl α(WT) + β-mYFP and dsRED (ER marker) viewed independently and with colocalization 
color scale. Image brightness and contrast was adjusted to compare neuronal processes and soma 
separately.  B. Average of all positive nMDP values represents the extent of β subunit localization in the 
ER. Mutation of the (β)RSR motif probably prevents ER-associated degradation of the β subunit.    
 
Newly synthesized, improperly folded, or unassembled Cys-loop subunits 
remaining in the ER are degraded rapidly43-47. Mutation of an ER retention motif may 
influence subunit degradation. To determine the relative amounts of WT and mutated β 
subunits remaining in the ER, a similar pixel-by-pixel colocalization analysis was used. 
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Rat hippocampal neurons were cotransfected with α(WT) and various β-mYFP subunits 
along with the fluorescent ER marker, dsRED. Once again, the (β)RSR_AAA mutant 
was significantly different from WT, (β)RRR_AAA and (β)RSR_AAA&RRR_AAA 
receptors, showing increased colocalization with ER marker  (Figure 4-22). This suggests 
that the β-mYFP RSR_AAA subunit is not being degraded at the same rate as β-mYFP, 
leaving more available for heteromeric assembly with α subunits. 
 
An optimized neuronal silencing tool 
Mutational screening in HEK293 cells lead to an engineered receptor with increased 
sensitivity to IVM. Functional data implied that the (β)RSR_AAA mutation increases β 
subunit incorporation in HEK293 cells and imaging experiments confirmed this 
mutational effect in neurons. To determine if the newly engineered GluCl α-mXFP L9’F 
+ β-mXFP Y182F RSR_AAA receptor is indeed an improved silencing tool over the 
original α-XFP + β-XFP Y182F receptor, in vitro recordings of IVM-induced spike 
inhibition were obtained from rat hippocampal neurons. Initially, gap-free recordings 
were acquired in current clamp mode with bath perfusion of IVM. Continuous recordings 
were interrupted by two current-injection step protocols, (-100 to 250 pA, 25 pA 
increments), one following two minutes of bath solution (baseline) and the other after 5 
min of 5 nM IVM perfusion. Spontaneous spiking varied from zero to high frequency 
bursts for transfected and nontransfected neurons. A decrease in spike frequency was not 
always observed within the duration of IVM application, but greater current injection was 
often required for spike generation following IVM perfusion (Figure 4-23A).  
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Several concerns were associated with the bath perfusion protocol including 
inherent spike variability and run-down effects from internal solution exchange. It also 
required large solution volumes and the ability to maintain seal resistance for an extended 
period of time (~10 minutes). Furthermore, variations in real-time silencing may not 
accurately depict improved sensitivity since it may require up to 15 minutes to achieve 
full spike inhibition by IVM1. For that reason, an alternative pre-incubation procedure 
was used to ensure adequate time for IVM activation and to avoid submitting patched 
neurons to lengthy perfusions. Cultured neurons were incubated with 0, 1, or 20 nM IVM 
for 15 minutes at 37°C/5% CO2, washed and then recorded for a V-I relationship using 
the current-injection step protocol (Figure 4-23B and 4-24A). Nontransfected neurons 
were not influenced by the presence of IVM and construct expression itself had no effect 
on resting membrane potential (Figure 4-24C). The newly engineered GluCl α-mYFP 
L9’F + β-mYFP Y182F RSR_AAA receptor shows a significant increase in conductance 
(as determined by the inverse slope, Figure 4-24D) and a lower mean spike count (Figure 
4-24B) for both 1 nM and 20 nM IVM compared to the original α-YFP + β-YFP Y182F 
silencing tool. Thus, GluCl α-mXFP L9’F + β-mXFP Y182F RSR_AAA, is an optimized 
construct for IVM-induced spike inhibition.  
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Figure 4-23.  Protocols for neuronal silencing by GluCl/IVM in vitro. Current clamp recordings of rat 
hippocampal neuron firing were obtained in response to depolarizing current pulses (-100 to 250 pA, 25 pA 
increments).  A. Continuous recording with IVM bath perfusion was a suboptimal method for comparative 
silencing effects. The neuron depicted was expressing the original silencing tool. (This neuron did not 
exhibit spontaneous firing.)  B. A 15-minute pre-incubation of 0, 1, or 20 nM IVM better elucidated a 
concentration-dependent silencing effect. The optimized construct (α-mYFP L9’F + β-mYFP Y182F 
RSR_AAA; bottom panel), is more sensitive to IVM than the original silencing tool (α-YFP + β-YFP 
Y182F; middle panel), and nontransfected control neurons (top panel). 
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Figure 4-24.  An optimized neuronal silencing tool.  Current clamp recordings of rat hippocampal neuron 
firing in response to depolarizing current pulses (-100 to 250 pA, 25 pA increments) were obtained 
following a 15-min pre-incubation of 0, 1, or 20 nM IVM.  A. V-I plots from neuronal cultures transfected 
with the optimized construct (α-mYFP L9’F + β-mYFP Y182F RSR_AAA) were compared to the original 
construct (α-YFP + β-YFP Y182F) and nontransfected neurons. The optimized receptor exhibits lower 
slope resistance at 1 and 20 nM IVM.  B. The optimized receptor also reduced mean evoked spike counts at 
1 and 20 nM IVM.  C. Neither construct expression or the presence of IVM alone significantly altered the 
resting membrane potential.  D. The optimized receptor induces a significant increase in conductance 
(determined by the inverse slope) at both 1 and 20 nM IVM compared to the original silencing tool.	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Discussion 
Previous reports state that both α and β subunits are required for neuronal silencing by 
IVM in vitro and in vivo1,13. Variability in GluCl channel expression levels, particularly 
with the β subunit, appeared responsible for whether or not an individual neuron was 
inhibited by IVM. It turns out that functional IVM-sensitive α homomers are also 
expressed at the plasma membrane and that enhanced β subunit incorporation can 
increase IVM sensitivity. A mixed presence of heteromeric and homomeric receptors 
within individual neurons may account for the observed variations in spike suppression.  
The original GluCl silencing tool has been re-engineered, introducing three new 
amino acid modifications: the (α)L9’F and (β)RSR_AAA mutations increase IVM 
sensitivity, probably by altering receptor stoichiometry; the monomeric XFP mutation 
helps maintain the increased IVM sensitivity upon reintroduction of a glutamate 
insensitive mutation by relieving the adverse effects of fluorescent protein 
oligomerization on receptor stoichiometry and function.  
 
Mechanisms of the optimized receptor 
In Chapter 2, experiments involving (α)L9’F homomers and heteromers show 
incorporation of the β subunit significantly increases sensitivity to IVM. The transfection 
ratio experiment of the current study not only substantiates this claim, but also implies 
that the (α)L9’F mutation prefers or possibly promotes β subunit incorporation. Biasing 
for α subunit expression with a 4α:1β ratio still yields a two-component IVM 
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concentration-response curve for this mutant. Even the low sensitivity component of this 
curve (EC50 = 150 nM) is more sensitive than that of (α)L9’F homomers (EC50 = 450 
nM). According to one theory of Cys-loop receptor assembly, subunits initially dimerize 
then two dimers subsequently incorporate a fifth subunit to form an assembled pentamer 
(reviewed in48). The (α)L9’F mutation may either promote α-β dimerization or hinder α-
α dimerization by means of intermolecular forces or steric preferences, resulting in a 
predominantly heteromeric αβ receptor population including more β subunits per 
assembled receptor. 
The fluorescent fusion proteins YFP and CFP are interchangeable between α and 
β subunits. However, presence of an XFP insertion in the α subunit reduced the IVM 
sensitivity of both α homomers and αβ heteromers compared to nontagged receptors, 
suggesting an interference with receptor function. Introduction of an A206K mutation for 
monomeric XFP alleviated this reduction. The mXFP tag also introduced a modest high 
IVM sensitivity component for the heteromeric nonmutant receptor and further enhanced 
the high sensitivity component of the heteromeric (α)L9’F mutant receptor, implying 
XFP oligomerization affected stoichiometry as well. 
The β subunit requires masking of an arginine-based ER retention motif by co-
assembly with the α subunit to exit the ER; β homomers are not trafficked to the plasma 
membrane. In the presence of α, the (β)RSR_AAA retention mutation increases the 
amount of β at the plasma membrane. The (β)RSR_AAA mutation also elevates β 
subunit levels in the ER, indicating that it does not simply enhance β subunit surface 
expression by reducing ER retention. Mutation of putative ER retention motifs alone 
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were not sufficient to allow surface expression of β homomers, suggesting an additional 
unknown quality control motif is likely involved in the retention mechanism. Instead, the 
(β)RSR_AAA mutation probably impedes ER-associated degradation of the β subunit, 
either directly, by preventing targeted degradation thereby prolonging its availability for 
α-β dimerization, or indirectly, by facilitating stable α-β dimer formation consequently 
preventing its degradation. Either way, the (β)RSR_AAA mutation promotes heteromeric 
receptor assembly evident by the biphasic IVM concentration-response curve. Though it 
is clear that α homomers are capable of forming functional channels at the plasma 
membrane, it is unknown to what extent their presence is maintained when β subunits are 
available. Limiting β subunit degradation may keep α homomer expression to a 
minimum. A reduced level of α subunit surface expression was confirmed with the 
(β)RSR_AAA mutation, however, it cannot be determined if the prevalence of α 
homomer expression was reduced or if the stoichiometry of αβ heteromeric expression 
was simply shifted to include fewer α subunits per assembled receptor. 
Contrary to initial functional assays on the FlexStation, the (β)RSR_AAA 
mutation does not increase total surface expression. The magnitude of RFU signal from 
the FlexStation can be influenced by a number of variables, including cell density in the 
well, transfection efficiency, receptor expression levels, and changes in receptor efficacy 
and should therefore be interpreted with caution. Like the (α)L9’F mutation, the 
(β)RSR_AAA mutation gives rise to a biphasic IVM concentration-response, but a 
monophasic glutamate concentration-response. Though the (α)L9’F and (β)RSR_AAA 
mutations may not provide a homogeneous receptor population, the populations present 
have significantly increased IVM sensitivity compared to that of the original silencing 
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tool, likely eliminating a major contributing factor of suboptimal firing inhibition. During 
in vitro recordings, variability in spike suppression was observed from cell-to-cell with 
both the original and optimized receptor tools, but was comparable to the variable 
number of evoked spikes observed from a nontransfected cell. Smaller error bars in the 
mean spike counts suggest reduced variability in spike suppression with the optimized 
receptor. 
 
Biphasic curves are due to shifts in stoichiometry 
As mentioned, the biphasic concentration-response curve observed with heterologous 
expression of the optimized GluCl receptor in HEK293 cells is probably the result of 
multiple receptor populations. Other subunits of the Cys-loop receptor family are known 
to exist in multiple stoichiometries. For example, α4β2 nicotinic acetylcholine receptors 
(nAChRs) form two stoichiometric populations with subunit ratios of 2α:3β and 3α:2β 
constituting high and low sensitivity receptors, respectively49-51. The glycine receptor 
(GlyR), which is the closest mammalian homolog to GluCl, forms functional channels as 
α homomers and αβ heteromers in mammalian expression systems52. The α homomers 
predominate during embryonic and neonatal development while heteromeric αβ GlyRs 
exist in the adult53, though the precise heteromeric stoichiometry, 3α:2β54 or 2α:3β55, has 
been debated.  
It is not clear if the stoichiometric GluCl populations present in HEK293 cells 
coincide with those present in neurons. IVM concentrations required for GluCl activation 
in HEK293 cells are higher than that required for silencing in neurons. According to the 
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FlexStation assays of the current study, the IVM EC50 for αβ WT GluCl in HEK293 cells 
is around 100 nM. In neurons, the EC50 for IVM-induced conductance measurements of 
αβ WT GluCl was reportedly 1.3 nM12. The time allowed for IVM activation and the 
method of detection certainly influences these measurements. For example, this ~1 nM 
IVM EC50 can be achieved in HEK293 cells for the WT receptor following lengthy (1 
hour) pre-incubation with low concentrations of IVM (see Chapter 5, Figure 5-3). The ~1 
nM EC50 also corresponds with the high sensitivity component of optimized receptor 
activation in HEK293 cells, observed as an increasingly robust signal within seconds to 
minutes. Discrepancies in IVM EC50 could be dependent on cell-type with different 
preferences for receptor stoichiometry or different posttranslational modifications that 
alter receptor activation. For example, homogeneous receptor populations can often be 
obtained by biasing transfection ratios in Xenopus oocytes49. Attempts to bias GluCl 
subunit expression in HEK293 cells did alter the shape of the IVM concentration-
response but did not produce a monophasic high sensitivity curve. Mammalian cells 
likely possess cell-specific machinery for more regulated receptor trafficking compared 
to Xenopus oocytes. Similarly, neurons may possess alternative posttranslational 
processing and regulatory mechanisms than standard mammalian cell lines. 
 
Implications of the glutamate insensitive mutation 
The (α)L9’F gain-of-function mutation facilitates β subunit incorporation to substantially 
increase heteromeric GluCl αβ sensitivity to IVM. Reintroduction of a glutamate 
insensitive mutation, either (β)Y182F or (β)Y232A, to the (α)L9’F mutant eliminated the 
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increase in IVM sensitivity. Whether this attenuation was an actual defect of structure-
function or a consequence of altered stoichiometry is unclear. Mutation of the L9’ residue 
is known to directly impact channel gating. The glutamate insensitive mutations are 
located within the glutamate binding site of the extracellular domain, some 60 Å away 
from the (α)L9’F mutation at the channel pore. Some residues at or near the binding site 
serve as gating pathway residues, engaging in long-range functional coupling to transmit 
binding events to the channel gate. Mutation of such a residue in combination with an L9’ 
mutation can produce a nonmultiplicative EC50, indicating the distant residues are 
functionally coupled56. Evaluation of the glutamate insensitive mutations by mutant cycle 
analysis in this case is complicated by the biphasic IVM concentration-dependence (i.e., 
two EC50 values) of the (α)L9’F mutation. Alternatively, mutations at or near the 
glutamate binding site which is positioned at subunit interfaces, could conceivably affect 
heteromeric subunit assembly. In this instance, the (β)Y182F or (β)Y232A mutations 
would be preventing efficient incorporation of the β subunit to eliminate the high IVM 
sensitivity component of the (α)L9’F mutant. The (α)Y261A mutation, which resulted in 
a predominantly α homomer population, supports the notion that mutations in this region 
can affect heteromeric receptor formation. Restoration of the high IVM sensitivity 
component by the mYFP mutation further supports that an altered subunit stoichiometry 
is responsible for the counteracting effects of the glutamate insensitive and (α)L9’F 
mutations. 
Combining the (α)L9’F mutation with the (β)Y182F glutamate insensitive 
mutation did recover some glutamate sensitivity in the concentration range tested, 
generating concern that this could allow constitutive silencing. Baseline concentrations of 
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extracellular glutamate in vivo are in the nanomolar range57 as glutamate transient decay 
is dependent on diffusion and uptake by membrane-bound transporters58. In the synaptic 
cleft of glutamatergic synapses, glutamate can reportedly reach as high as 1 mM59,60, 
though this concentration has been contested61, arguing the amount of transmitter 
released is highly variable and often nonsaturating62,63. Thus, it is not certain that this 
level of glutamate sensitivity will be detrimental to in vivo silencing applications. 
Punctate immunostaining patterns are suggestive of a synaptic localization for 
exogenously expressed GluCl receptors. Similar inhibitory receptors such as GlyR and 
GABAA are known to be clustered at synapses by binding of the anchor protein gephrin, 
which recognizes an 18-amino acid binding motif in the intracellular loop of the 
respective β subunit64. Sequence alignments indicate that neither GluCl α nor β subunits 
possess a gephrin binding motif, discounting the likelihood of clustering by this 
mechanism. Synaptic localization could be easily confirmed or denied by colocalization 
experiments with a postsynaptic density marker. If necessary, additional protein 
engineering strategies may be applied to the optimized GluCl tool to relieve synaptic 
receptor clustering.  
 
Application of GluClv2.0 
Since the initial proof-of concept study, the original GluCl/IVM tool has been used in 
conjunction with Channelrhodopsin-2-mediated activation to define an inhibitory 
microcircuit within the amygdala involved in mouse fear conditioning65 and to identify a 
hypothalamic locus responsible for male mouse aggression and its close neuroanatomical 
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relationship to mating circuits66. An intersectional approach was used in former study to 
restrict GluCl expression to PKC-δ-containing GABAergic neurons of the central 
amygdala. This was achieved by transgenic expression GluCl α-CFP in all PKC-δ+ 
neurons followed by stereotaxic injection of an AAV vector encoding GluCl β-YFP 
Y182F. While GluCl/IVM-induced silencing of PKC-δ+ neurons yielded a statistically 
significant enhancement of conditional freezing, this behavioral result was confounded 
by a bimodal phenotype. Quantitative histological analysis again revealed considerable 
variation in expression of the virally injected β subunit among individual animals, 
reminiscent of the striatal proof-of-concept studies. Control animals transgenically 
expressing α alone or wild-type animals injected with β alone were not affected by 
treatment with 10 mg/kg IVM. While the present study confirms that α homomers are 
indeed trafficked to the plasma membrane, it raises the question of whether α homomer 
activation elicits sufficient chloride current to achieve neuronal silencing. For example, 
current responses recorded from GluCl α homomers expressed in Xenopus oocytes are 
10-fold smaller than the αβ heteromeric responses11,40. A type of small slow-activating 
IVM-induced current has also been recorded from HEK293 cells which may result from 
α homomer expression, though this has not yet been confirmed (see Chapter 5, Figure 
5.2). Additional in vitro neuronal silencing experiments should be conducted to compare 
the spike suppression capability of α homomers to αβ heteromers. Nevertheless, an 
intersectional approach is apparently still practical.  
The optimized GluCl receptor, α-mXFP L9’F + β-mXFP Y182F RSR_AAA, 
dubbed ‘GluCl version 2.0’ or simply ‘GluClv2.0’, maintains the requirement for both α 
and β subunits. The new sequence modifications significantly improve receptor 
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sensitivity and subunit expression by preventing degradation of the β subunit and 
promoting its dimerization with the α subunit, in addition to relieving both subunits from 
the adverse effects of XFP oligomerization. The kinetic properties of the silencing tool 
have not been altered. An alternative orthogonal pharmacological silencing tool capable 
of activating and inactivating on shorter time scales has recently been constructed67. This 
tool employs chimeric nAChR-GlyR receptors of mammalian origins. The cognate 
synthetic nicotinic agonist has demonstrated weak to moderate binding of other 
endogenous nAChRs and the lack of co-assembly of chimeric subunits with endogenous 
nAChR subunits has not been verified. Even faster time-resolved neuronal silencing can 
be achieved using optogenetic techniques68,69. This method, however, is invasive and 
requires implantation of optical fibers that do not allow for manipulation of diffuse 
signaling networks. The duration of light-induced manipulation is also limited by heat 
generation which may alter neuronal activity or be damaging to cell health70. A separate 
attempt at improving IVM-induced silencing has also been made by modification of 
GlyR71. A single point mutation increased IVM sensitivity of GlyR by 100-fold, allowing 
activation in the nM range (i.e., similar to the original GluCl tool), while a separate point 
mutation eliminated glycine sensitivity. This modified GlyR tool has not been 
implemented in vivo. Future circuitry studies with this tool would be dependent on the 
assumption that endogenous GlyR expression is confined to spinal cord and brainstem 
neurons72. Experimental evidence, in fact, suggests a more widespread distribution of 
GlyR expression including higher brain regions such as the hippocampus, thalamus, 
amygdala, caudate-putamen and cerebral cortex73-79. Modified GlyRs would likely co-
assemble with endogenous subunits yielding obscure results. GluCl receptors, on the 
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other hand, do not exist in mammalian neurons and GluClv2.0 manifests even greater 
sensitivity to IVM. We therefore believe the GluCl/IVM tool remains relevant and fills a 
niche for behavioral assays necessitating long-term neuronal inhibition (e.g., learning 
paradigms) and for assessing modulatory as opposed to regulatory roles in circuitry.  
The aim of this project was to produce an optimized GluCl silencing tool via 
rational protein engineering strategies. Throughout this pursuit, a great deal has been 
learned about structure-function relationships and subunit expression patterns of GluCl. 
While the system is still not perfectly understood, the success of GluClv2.0 as an 
improved silencing tool has been demonstrated in vitro. The increased sensitivity and 
improved subunit expression of GluClv2.0 should allow lower doses of IVM to be 
administered for in vivo silencing, thereby alleviating concerns of off-target side effects 
and reducing the occurrence of suboptimal inhibition.  
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Materials and Methods 
Site-Directed Mutagenesis 
Codon optimized sequences of the Caenorhabditis elegans GluCl channel cloned into 
plasmid vector pcDNA3.1/V5-His TOPO (Invitrogen #K4800-01), including optGluCl 
αWT, optGluCl βWT, optGluCl α-XFP, and optGluCl β-XFP12, were used in this study. 
Fluorescent protein insertions (XFP) include enhanced yellow (YFP) and cyan (CFP) 
variants and are located in the TM3-TM4 loop11. All constructs originate from the 
optimized codon sequences. For convenience, the ‘opt’ nomenclature has been omitted 
throughout most of this text. Point mutations were made using the QuikChange II XL 
site-directed mutagenesis kit (Agilent Technologies #200522) with PfuTurbo DNA 
polymerase (Agilent Technologies #600250). Forward and reverse primers for the 
(α)L9’F mutation are listed in Chapter 3. Mutant subunits in the current study were 
generated with the following forward and reverse primers (new codon is italicized in the 
forward primer): 5’ – GGC GTG ACC ACC CTG TTC ACC ATG ACC ACC ATG – 3’ 
and 5’ – CAT GGT GGT CAT GGT GAA CAG GGT GGT CAC GCC – 3’ for the 
(β)L9’F mutation; 5’ – AC TTC GAC CTG GTG TCC TTC GCC CAC ACC – 3’ and 5’ 
– GGT GTG GGC GAA GGA CAC CAG GTC GAA GT – 3’ for the (β)Y182F 
mutation; 5’ – C AAC ACT GGC TCG GCC GGC TGC CTG CGC – 3’ and 5’ – GCG 
CAG GCA GCC GGC CGA GCC AGT GTT G – 3’ for the (β)Y232A mutation; 5’ – 
ACC AAC ACC GGC ATC GCC AGC TGC CTG AGG AC – 3’ and 5’ – GT CCT 
CAG GCA GCT GGC GAT GCC GGT GTT GGT – 3’ for the (α)Y261A mutation; 5’ – 
TAC CTG AGC TAC CAG TCC AAG CTG AGC AAA GAC CCC AAC – 3’ and 5’ – 
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GTT GGG GTC TTT GCT CAG CTT GGA CTG GTA GCT CAG GTA – 3’ for the 
monomeric YFP A206K mutation; 5’ – TG CGC CAG AAC GAC GCC GCC GCC 
GAG AAG GCG GCC C – 3’ and 5’ – G GGC CGC CTT CTC GGC GGC GGC GTC 
GTT CTG GCG CA – 3’ for the (β)RSR_AAA mutation; 5’ – CG GCC CGC AAG GCC 
CAG GCA GCC GCC GAG AAG CTG GAG ATG G –3’ and 5’– C CAT CTC CAG 
CTT CTC GGC GGC TGC CTG GGC CTT GCG GGC CG – 3’ for the (β)RRR_AAA 
mutation. The C-terminal tags V5 and 6-His are included in the plasmid vector and were 
added to the α and β subunits by point mutation of the stop codon with the following 
primers: 5’ – G CAG AAC GTT CTG TTC GGA GCT AGC AAG GGC AA – 3’ and 5’ 
– TT GCC CTT GCT AGC TCC GAA CAG AAC GTT CTG C – 3’ for the α subunit; 5’ 
– CC GAG TCC CTG GTG TTG GCT AGC AAG G – 3’ and 5’ – C CTT GCT AGC 
CAA CAC CAG GGA CTC GG – 3’ for the β subunit. All mutations were confirmed by 
DNA sequencing. 
 
Cell culture 
HEK293 cells were cultured, plated and transfected for electrophysiology and 
FlexStation assays as described in Chapter 3. For TIRF imaging experiments, HEK293 
cells were plated on 35 mm glass bottom culture dishes (MatTEK #P35G-1.5-10-C) at 
50,000 cells/dish and transfected following the same protocol used for the 
electrophysiology experiments described in Chapter 3. For Western blot analyses, 
HEK293 cells were plated in 10 cm dishes at 4×106 cells/dish and transfected with 16 µg 
DNA in 500 µl DMEM combined with 30 µl ExpressFect (Denville Scientific #E2650) in 
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500 µl DMEM that was preincubated for 20 minutes before adding to culture dishes 
containing 5 ml fresh culture medium. The transfection mix was removed after 4–6 hours 
and replaced with 10 ml of fresh culture medium. For all experiments, HEK293 cells 
were transfected 24 hours after plating and assayed 48 hours after transfection. 
Hippocampal neurons were extracted from day 18 Wistar rat embryos80 and 
plated at a density of 40,000 cells per dish on 35 mm glass bottom culture dishes coated 
with poly-DL-lysine (Sigma #P9011). Neurons were cultured in Neurobasal medium 
(Gibco #21103-049) containing 2% B27 (Gibco #17504-044), and 0.5 mM Glutamax 
(Gibco #35050). Medium was supplemented with 5% equine serum (Hyclone #SH30074) 
during plating. Cultures were maintained at 37°C and 5% CO2 in a humidified incubator, 
with a 50% media exchange once per week. For imaging experiments, neurons were 
treated with 1 µM cytosine arabinoside (AraC; Sigma #C1768) on culture day 10 with a 
100% media change the following day. Cultures used for electrophysiological 
experiments were not treated with AraC. Neurons were transiently transfected after 13-14 
days in culture and assayed 24 hours later. Transfections were prepared per dish using 4 
µg of plasmid DNA with 20 µg Nupherin-neuron (BIOMOL #SE-225) and 10 µl of 
Lipofectamine 2000 (Invitrogen #11668-019) diluted separately in 400 µl of Neurobasal 
without phenol red (Gibco #12348-017). Dilutions were individually incubated at room 
temperature for 15 minutes, then combined and incubated for another 45 minutes. An 800 
µl volume of conditioned media was then removed from the neuronal culture dish and 
replaced with the 800 µl transfection mix. After incubating cultures for 1 hour at 
37°C/5% CO2, an 800 µl volume was removed from the dish and replaced with the 
original 800 µl of conditioned media.  
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Membrane Potential Measurements 
Membrane Potential assays were performed on the FlexStation 3 multimode benchtop 
microplate reader using the BLUE formulation kit (Molecular Devices, #R8042) with the 
same dye preparation and data acquisition parameters described in Chapter 3. Glutamate 
and IVM drug preparation and dose-response data analysis is also described in Chapter 3. 
 
Electrophysiology 
Voltage-clamped HEK293 cells were recorded as described in Chapter 3. Neurons were 
whole-cell current-clamped using an Axopatch 200A amplifier with a CV201 headstage 
and Digidata 1200 series interface operated by Clampex 9.2 software (Axon 
Instruments). Spontaneous neuronal firing was recorded in Gap-free acquisition mode. 
Episodic Stimulation acquisition mode was used for executing stepwise current injections 
(-100 to 250 pA, 25 pA increments) to record evoked spike firing. Data was sampled at 
50 kHz and lowpass filtered at 5 kHz. Neurons were perfused or incubated with artificial 
cerebrospinal fluid (ACSF) composed of (in mM): 110 NaCl, 5.4 KCl, 1.8 CaCl2, 0.8 
MgCl2, 10 D-glucose, 10 HEPES, pH 7.4, 230 mOsm. Patch pipettes were made from 
borosilicate glass with resistances of 7–12 MΩ when filled with the following internal 
solution (in mM): 100 K-gluconate, 0.1 CaCl2, 5 MgCl2, 1.1 EGTA, 10 HEPES, 3 Mg-
ATP, 0.3 GTP, 3 phosphocreatine, pH 7.2, 215 mOsm. IVM was dissolved in ACSF 
containing 0.1% DMSO and applied to cultures by bath perfusion or pre-incubation at 
37°C/5% CO2 for 15 minutes. All recordings were performed at ambient temperature. 
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Data was analyzed using Clampfit 9.2 software. Resting membrane potential was 
measured in the absence of any injected current and corrected for the liquid junction 
potential. Cells with a resting membrane potential of > −45 mV or with a seal resistance 
of < 100 MΩ or were omitted from analysis. The steady-state voltage response was 
plotted against the amount of current injected for a voltage-current (V-I) relationship. 
Input resistance of the cell was determined from the slope, according to Ohm’s law, V = 
IR. Conductance was calculated as the inverse of resistance (G = 1/R = I/V). Induced 
spikes were counted manually and plotted against injected current. 
 
Immunofluorescent labeling 
Live, nonpermeabilized neurons were immunolabeled according to the protocol described 
in Glynn & McAllister, 200681. A V5 epitope tag (GKPIPNPLLGLDST) followed by a 
6-His tag (HHHHHH) already encoded in the pcDNA3.1 vector was added to the C-
terminus of GluCl α and β subunits (including a 24-residue linker sequence, see Figure 4-
19A) by mutation of the stop codon (see Site-Directed Mutagenesis). The 6-His tag was 
not utilized in these experiments. Surface receptors were labeled with primary mouse 
monoclonal anti-V5 antibody (1:200; Invitrogen #R960-25) followed by a conjugated 
secondary Alexa Fluor 555 donkey anti-mouse antibody (1:400; Invitrogen #A-31570). 
Antibodies were diluted into warm ACSF and applied sequentially, incubating each for 
30 min at 37°C/5% CO2 with appropriate wash steps. Live immunostained cultures were 
imaged immediately. 
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Western Blot Analysis 
Whole-cell lysates were obtained from transiently transfected HEK293 cells using ice 
cold extraction buffer containing (in mM): 50 Tris, 50 NaCl, 1 EDTA, 1 EGTA, pH 7.4 
and 1% NP40 supplemented with 1% protease inhibitor cocktail (Thermo Scientific 
#78410). The cell surface receptors were biotinylated and isolated for Western blot 
analysis using the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific #89881). 
Cell samples (30 µl) were separated on ‘Any kD’ Mini-PROTEAN TGX Precast gels 
(Bio-Rad #456-9033) in Tris/Glycine/SDS running buffer (Bio-Rad #161-0732) at 200 V 
for 35 minutes. Gel bands were transferred onto presoaked Protran nitrocellulose 
membranes (Whatman #10485376) in buffer containing 20% methanol and 10% Tris-
glycine SDS at 15 V for 20 minutes. Nitrocellulose membranes were initially blocked in 
10% milk in TBST (TBS + 0.1% Tween-20; Bio-Rad #170-6435, Sigma #P1379) and 
then incubated with rabbit anti-GFP antibody (1:1000; Invitrogen #A11122) in 5% BSA 
in TBST with 10% NaN3 overnight to probe for GluCl β-mYFP subunit expression. 
Protein bands were detected by enhanced chemiluminescence (Western Lightning Plus-
ECL; PerkinElmer #NEL103001EA) using goat anti-rabbit horseradish peroxidase 
(1:5000; Promega #W4011) in 5% BSA in TBST and developed on film (Amersham 
Hyperfilm ECL). The ~72 kDa molecular weight band was identified using the SeeBlue 
Plus2 prestained protein standard (Invitrogen #LC5925). ImageJ software (National 
Institutes of Health; http://rsb.info.nih.gov/ij/) was used for quantification of band 
intensity. 
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Imaging 
All cultured neurons and HEK293 cells and were imaged live at 37°C in a stage-mounted 
culture dish incubator (Warner Instruments). Transiently transfected HEK293 cells were 
imaged by Total Internal Reflection Fluorescence (TIRF) microscopy, which enabled 
visualization of fluorescent receptors expressed in the plasma membrane and nearby 
intracellular vesicles within 200 nm of the cell-coverslip interface. Prior to imaging, cell 
culture medium was replaced with phenol red-free CO2-independent Leibovitz L-15 
medium (Gibco #21083-027). TIRF images were obtained using an inverted microscope 
(Olympus IX81) with a 100x/1.45 NA Plan Apochromat oil objective. A T-cube stepper 
motor (Thorlabs) was used to control the position of the fiber optic and TIRF evanescent 
field illumination. A 488 nm laser was used to excite monomeric YFP fluorescence. 
Images were acquired with MetaMorph Premier software (Molecular Devices) at 16-bit 
resolution over 512×512 pixels and captured using a back-illuminated EMCCD camera 
(iXON DU-897) supported by ANDOR iQ2 software (Andor Technology).  
Transiently transfected hippocampal neuron cultures were imaged using a laser-
scanning confocal microscope (Nikon Eclipse C1si) with a 63x/1.4 NA VC Plan 
Apochromat oil objective. Monomeric YFP fluorescence was acquired with 514 nm laser 
excitation. Alexa 555 and pDsRED2 (Clontech #632409) fluorescence was acquired with 
561 nm laser excitation. Images were collected as z-stacks at a step size of 1.0 µm with 
16-bit resolution over 512×512 pixels and a dwell time of 6.72 µs. 
For confocal image analysis, the two different fluorescent signal intensities were 
correlated on a pixel-by-pixel basis using the Colocalization Colormap ImageJ plug-in 
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(Adam Gorlewicz, http://sites.google.com/site/colocalizationcolormap/home) based on 
the algorithm by Jaskolski et al., 200582. The correlation of a pair of pixels was calculated 
as follows: 
 
 Ia intensity for the given pixel in image a 
  average intensity of image a 
 Iamax  the highest pixel intensity in image a 
 Ib intensity for the given pixel in image b 
  average intensity of image b 
 Ibmax  the highest pixel intensity in image b 
 
The normalized mean deviation product (nMDP) values for each pixel range from −1 to 1 
and can be visualized on a color scale. Values < 0 are represented by cold colors for 
exclusion and values > 0 are shown in hot colors for colocalization. Zero values indicate 
black background. For the experimental conditions of the current study, the average of all 
positive (colocalized) nMDP values corresponds to total receptor surface expression, 
while the average number of perfectly correlated pixels (i.e., where nMDP = 1) indicates 
the relative amounts of each receptor subunit. 
 
 
!  
! 
nMDPx,y =
(Ia " Ia)(Ib " Ib)
(Iamax " Ia)(Ibmax " Ib)
!  
! 
Ia
!  
! 
Ib
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Statistics 
Pooled data are shown as means ± SEM. Boxplots represent the mean, median, 25th, and 
75th percentiles. Statistical significance (P < 0.05) was determined by one-way analysis of 
variance (ANOVA) on ranks using multiple pairwise comparison. 
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Chapter 5 
 
Addendum 
 
The present study utilized mammalian HEK293 cells as a model expression system for 
screening mutational effects of the GluCl receptor. As discussed in Chapter 3, much cell-
to-cell variability was observed during electrophysiology experiments on L9’ mutants. 
Additional functional assays performed for silencing tool optimization, supplemental to 
those presented in Chapter 4, also displayed a great deal of variability and are the subject 
of this addendum. 
Prior to introducing the monomeric YFP mutation, negative effects on IVM 
sensitivity imparted by the fluorescent protein insertion in the α subunit were first 
investigated by simple extraction of the YFP tag. Removal of YFP from the α subunit of 
(α)L9’F, (β)Y182F, and (β)RSR_AAA mutant receptors yielded ambiguous results 
(Figure 5-1A, B, C). Individually, the removal of YFP from α increased the high 
sensitivity component of the (α)L9’F mutant but eliminated the high sensitivity 
component from the (β)RSR_AAA mutant, while the (β)Y182F mutant remained 
unchanged. Assorted combinations of these mutations were equally puzzling (Figure 5-
1D).  
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Figure 5-1.  Removal of YFP from the α  subunit affects IVM sensitivity.  IVM activation was assayed 
using the FlexStation. Normalized IVM concentration-response curves showing removal of the YFP tag 
from the α subunit increased the high sensitivity component of the (α)L9’F mutant (panel A.) but 
eliminated the high sensitivity component from the (β)RSR_AAA mutant (panel C.) while IVM sensitivity 
of the (β)Y182F mutant (panel B.) was unchanged.  D. Normalized IVM concentration-response curves of 
assorted mutant combinations with (filled symbol) and without (open symbol) YFP on the α subunit did not 
reveal a consistent effect. 
 
In retrospect, oligomerization of the fluorescent fusion proteins presumably 
affected receptor stoichiometry in these experiments. The contradicting effects on the 
biphasic response of (α)L9’F and (β)RSR_AAA receptors, are in accordance with the 
proposed mutational implications. For example, in the ER, YFP oligomerization of α-α 
dimers, α-β dimers and β-β dimers presumably occur with the same prevalence. Removal 
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of YFP from the α subunit may boost its availability for the preferred α-β dimerization 
effect of the (α)L9’F mutation. This inadvertently reduces α-α dimerization while further 
promoting β subunit incorporation, visible by the enhanced high sensitivity component of 
the IVM concentration-response curve. The (β)RSR_AAA mutation, on the other hand, 
probably prevents β subunit degradation, but it does not have the heterodimer 
promotional effect of (α)L9’F. Because YFP tags of the β subunit were left intact, β-β 
dimers likely predominate, thereby sequestering the β subunit, resulting in primarily α 
homomer expression and a monophasic response.  
The biphasic IVM response of (α)L9’F mutant receptors (with YFP removed 
from α) exhibited the largest high sensitivity component observed at the time. The IVM-
induced currents associated with the two components of this mutant were examined by 
electrophysiology and compared to WT and (β)Y182F receptors (also with YFP removed 
from α). Whole-cell currents were recorded from transfected HEK293 cells in voltage-
clamp with bath perfusion of 1, 5, and 50 nM IVM. The kinetic response was highly 
variable, yet two modes of activation were observed: a “slow” mode requiring minutes to 
peak current with some evidence of recovery (Figure 5-2A, black lines) and a “slower” 
mode which did not peak within the 5-minute application of IVM, rather, it continued to 
increase even upon removal of IVM from the bath (Figure 5-2A, red lines). The current 
magnitude of “slower” mode responses often resembled the steady-state current of the 
“slow” mode response. Nevertheless, pooled data still indicate a significant increase in 
mean peak current for the (α)L9’F mutant at 1 nM IVM (Figure 5-2B) and normalization 
of the mean response reveals a significant increase in IVM sensitivity at both 1 and 5 nM 
IVM for (α)L9’F (Figure 5-2C). Interestingly, no “slower” responses were observed for  
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Figure 5-2.  Electrophysiology with IVM.  A. Whole-cell IVM-induced currents recorded from HEK293 
cells in voltage-clamp. IVM concentrations of 1, 5, and 50 nM were applied for 5 minutes by bath 
perfusion. Two modes of activation were observed: ‘slow’ (black traces) and ‘slower’ (red traces).  B. The 
(α)L9’F mutant shows a significant increase in mean peak current compared to WT at 1 nM IVM. The total 
number of cells recorded (black numbers) and the number of cells exhibiting ‘slower’ responses (red 
numbers) are indicated.  C. Response normalization shows a significant increase in IVM sensitivity at both 
1 and 5 nM IVM for (α)L9’F mutant.  
100 pA 
2 min 
!!"#$%&%"'()*# !!"#$%&%"'()*%(+,-)# ! ./0)%&%"'()*#
+%12%
3%12%
34%12%
562%
47+8%9:;<%
=>?@%;<A1%
!':()* ./0)%&%%
"':()*%(+,-)%BCBDEEE#
A 
0
200
400
600
800
1000
M
e a
n  
R
e s
p o
n s
e  
( p
A
)
0
00
00
00
00
00
 5 50 5 501 5 501 1 5 50 
0
00
00
00
00
00
 5 50 5 501 5 01 1 5 50 
0
00
00
00
00
00
 5 50 5 501 5 501 1 5 50 
!"#$%
#"&$%
'% #%
((")$%
!"*$%
+%
#%
'%
#"($%
)"($%
'%
B 
,%
!!"#$%&%"'()*#
!!"#$%&%"'()*%(+,-)#
! ./0)%&%"'()*%
!'1()*%./0)%&%"'1()*%(+,-)%2324555#
1 10 100
0.0
0.2
0.4
0.6
0.8
1.0
*
M
e a
n  
N
o r
m
a l
i z
e d
 R
e s
p o
n s
e  
[Ivermectin] (nM)
*
C 
	   153	  
the (α)L9’F mutant. At a much later date, similar recordings were obtained for the 
optimized receptor, α-mYFP L9’F + β-mYFP Y182F RSR_AAA. This receptor 
displayed both “slow” and “slower” type currents and did not appear to be significantly 
different from WT. These results were quite discouraging as they took place before 
neuronal silencing experiments.  
The variability observed in the electrophysiological recordings of GluCl in 
HEK293 cells with IVM may be related to the high and low sensitivity responses 
observed in electrophysiological recordings with glutamate (Chapter 3), but it is difficult 
to speculate on the cause. Whether the “slower" IVM-induced currents contribute 
significantly to the population-based concentration-response curves obtained on the 
FlexStation seems unlikely as the magnitude of the response is minimal even after 5 
minutes. It may be that “slower” currents are conducted by α homomers from cells that 
did not incorporate both α and β plasmid vectors during transfection. Since HEK293 
cells were also cotransfected with soluble GFP to select cells for recording, cells that may 
have been expressing only the α subunit with no YFP tag would still have been included. 
Such variability caused by transfection, however, seems improbable since HEK293 cells 
are typically transfected with high efficiency. Nonetheless, recording from HEK293 cells 
intentionally transfected with only the α subunit would easily determine if “slower” 
currents are in fact conducted by α homomers. 
Taking into account the slow activation kinetics of IVM and possible long-term 
accumulation of steady-state currents, mutants were incubated for 1 hour with varying 
concentrations of low IVM, and then assayed on the FlexStation using a single polarizing 
concentration of KCl to magnify the response. The EC50 concentration of 25 mM KCl 
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(Figure 5-3A, B) was used for the most sensitive detection of differential activation by 
low IVM and to avoid a saturating change in membrane potential. During the assay, 
addition of 25 mM KCl produced a negative signal (Figure 5-3C). This implies that long-
term application of low IVM depolarizes cells to such an extent, that addition of an 
otherwise depolarizing amount of KCl induces repolarization of the membrane. The 
range of repolarization produced by a single dose of KCl reveals that long-term 
application of low IVM induces depolarization in concentration-dependent manner 
(Figure 5-3D). As expected, the (α)L9’F mutation increased sensitivity to IVM. Addition 
of the (β)Y182F mutation still reduced the (α)L9’F effect, but this double mutant 
maintained a significant increase in IVM sensitivity compared to the original tool used 
for silencing.  
The A206K monomeric YFP mutation was essential toward the development of 
an optimized receptor. Even so, monomerization of YFP tags did not resolve the 
variability issues observed with GluCl in HEK293 cells. In the initial trial, the optimized 
GluCl α-mYFP L9’F + β-mYFP Y182F RSR_AAA receptor showed ~2 orders of 
magnitude greater sensitivity to IVM than the original tool used for silencing (Chapter 4, 
Figure 4-12). Both the optimized and original receptors were then assayed two additional 
times to ensure repeatability, and on average, the sensitivity improvement was 
maintained (Figure 5-4A). Examination of individual experiments, however, revealed the 
fraction of the high sensitivity component of the optimized receptor varied from day-to-
day (Figure 5-4B).  
 
	   155	  
	   	  
Figure 5-3.  Preincubation with low IVM induces a concentration-dependent response.  A&B. KCl-
induced depolarization of nontransfected HEK293 cells reveals an EC50 of 25 mM.  C. Transfected 
HEK293 cells were incubated for 1 hr with varying concentrations of low IVM, then assayed on the 
FlexStation with 25 mM KCl. Application of 25 mM KCl induced repolarizing (negative-going) signals in 
an IVM concentration-dependent manner.  D. Response normalization reveals significantly increased IVM 
sensitivity for (α)L9’F and (α)L9’F+(β)Y182F mutant receptors compared to the original silencing tool, 
(β)Y182F. 
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Figure 5-4.  Functional assay repeatability of the optimized vs. original receptor silencing tools.  IVM 
activation was assayed using the FlexStation.  A. Optimized receptor maintains increased IVM sensitivity 
following triplicate measurements. Ivermectin activation parameters are presented in the corresponding 
table.  B. Individual experiments reveal the high sensitivity component fraction of the optimized receptor 
varies from day-to-day. The consistent concentration-response of the original receptor ensures repeatability 
of the functional assay. 
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A host of additional experiments were subsequently performed in attempt to 
determine the source of this variability. Possible contributing factors tested included cell 
density, fresh culture media, fresh transfection reagent, the time posttransfection, and the 
passage number of the cells. All conditions produced a two-component curve with high 
sensitivity component fractions that varied remarkably (Figure 5-5A). Averaging all ten 
concentration-response curves of the optimized receptor still showed an improvement 
over the original silencing tool (Figure 5-5B, C). Time-dependent signal run-down was 
certainly a contributing factor, but it had been observed even with the WT receptor 
(Figure 5-6). Thus, the source of high IVM sensitivity variability remains to be 
determined.  
Despite the many issues with variability, FlexStation assays of GluCl mutant 
receptors in HEK293 cells still served as a successful screening method for generating an 
optimized neuronal silencing tool. Though the original α-XFP + β-XFP Y182F receptor 
was effective in silencing neurons, the optimized α-mXFP L9’F + β-mXFP Y182F 
RSR_AAA receptor is significantly improved. Functional experimentation throughout the 
optimization process has provided a better understanding of structure-function 
relationships and subunit expression patterns of the GluCl receptor.  
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Figure 5-5.  The high IVM sensitivity component of the optimized receptor is remarkably variable in 
HEK293 cells. IVM activation was assayed using the FlexStation.  A. Additional assays of the optimized 
receptor considered the influence of cell density, fresh culture media, fresh transfection reagent, the time 
posttransfection, and the passage number of the cells. All conditions produced a two-component curve with 
varying fractions of high IVM sensitivity. Ivermectin activation parameters are presented in the 
corresponding table. The source of variability was not determined.  B&C. Averaging all ten concentration-
response curves of the optimized receptor still shows increased sensitivity compared to the original 
silencing tool. 
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!!"#$%&'()$&*&"!"#$%&#+,-$&./.0111&&&++!28!++&&&%3456- 0.20 3.52 ± 4.93 1.00 ± 0.68 133.10 ± 16.40 1.96 ± 0.41 P13; 17,000 cells/well 
!!"#$%&'()$&*&"!"#$%&#+,-$&./.0111&&&++!-9!++&&&%3456+ 0.53 13.98 ± 12.40 1.17 ± 0.64 317.79 ± 130.56 2.50 ± 1.79 P18; new media; new expressfect 
!!"#$%&'()$&*&"!"#$%&#+,-$&./.0111&&&++!-9!++&&&%3456- 0.31 0.89 ± 0.44 2.50 ± 2.81 155.28 ± 41.67 2.36 ± 1.36 P18; new media 
!!"#$%&'()$&*&"!"#$%&#+,-$&./.0111&&&++!-,!++&&&%3456+ 0.63 7.26 ± 4.95 1.33 ± 0.63 191.35 ± 114.68 2.06 ± 2.82 P19; 24 hrs 
!!"#$%&'()$&*&"!"#$%&#+,-$&./.0111&&&++!-(!++&&&%3456+ 0.37 3.09 ± 15.78 1.18 ± 1.28 55.98 ± 114.63 1.00 ± 1.52 P19; 48 hrs 
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Figure 5-6.  Time-dependent run-down of RFU signal.  IVM activation was assayed using the 
FlexStation.  A. FlexStation experimental design. Different concentrations of IVM are applied to each well. 
The IVM-induced signal of column 1 is detected for five minutes before moving on to column 2. The time 
lag between IVM application and signal detection remains constant. One 96-well plate assay takes one hour 
to complete.  B. Two columns are combined for a single 15-point concentration response curve. Over time, 
from columns 1 and 2 (black) to columns 11 and 12 (magenta), raw signals are reduced in magnitude and 
concentration dependence is right-shifted.  C. Despite signal run-down, an exemplary normalized 
concentration-response relationship is well fit to the Hill equation. Chi2 per degrees of freedom = 0.00036. 
R2 = 0.99772. 	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